US20040006328A1 - Targeting of sebaceous follicles as a treatment of sebaceous gland disorders - Google Patents

Targeting of sebaceous follicles as a treatment of sebaceous gland disorders Download PDF

Info

Publication number
US20040006328A1
US20040006328A1 US10/612,599 US61259903A US2004006328A1 US 20040006328 A1 US20040006328 A1 US 20040006328A1 US 61259903 A US61259903 A US 61259903A US 2004006328 A1 US2004006328 A1 US 2004006328A1
Authority
US
United States
Prior art keywords
energy
material
infundibulum
skin
sebaceous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/612,599
Inventor
Richard Anderson
Original Assignee
Anderson Richard Rox
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US09/225,026 priority Critical patent/US6183773B1/en
Priority to US09/464,137 priority patent/US6600951B1/en
Application filed by Anderson Richard Rox filed Critical Anderson Richard Rox
Priority to US10/612,599 priority patent/US20040006328A1/en
Publication of US20040006328A1 publication Critical patent/US20040006328A1/en
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0028Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0052Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy

Abstract

Laser treatments of sebaceous gland disorders with laser sensitive dyes are disclosed. A preferred laser treatment includes topical application of an energy activatable material to the skin followed by laser irradiation.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. patent application Ser. No. 09/464,137, filed Dec. 16, 1999 which is a continuation-in-part of U.S. patent application Ser. No. 09/225,026, filed Jan. 4, 1999, the contents of which are incorporated herein by reference.[0001]
  • BACKGROUND OF THE INVENTION
  • Skin disorders, such as acne, can be irritating and embarrassing. The major disease of skin associated with sebaceous follicles, is acne vulgaris. This is also the most common reason for visiting a dermatologist in the United States. There are many treatments, but no cures for acne. These include antibiotics (which inhibit growth of [0002] p. acnes bacteria which play a role in acne), retinoids such as Accutane® (isotetinoin, which reduces sebaceous gland output of sebum), and antimicrobials such as benzoyl peroxide. Acne lesions result from the rupture of a sebaceous follicle, followed by inflammation and pus (a “whitehead”), or by accumulation of plugged material in the sebaceous follicle (a “blackhead”). This pathophysiology has two major requirements: (1) plugging of the upper portion of the follicle, and (2) an increase in sebum production. The upper portion of the follicle, i.e., the “pore” into which sebum is secreted and which is directly in communication with the skin surface, is called the infundibulum. A plug forms in the infundibulum from cells, sebum, bacteria, and other debris. The sebaceous gland continues to produce sebum (an oily fluid), stretching the infundibulum until either it or some lower portion of the follicles ruptures.
  • Generally, only a minority of sebaceous hair follicles on the face and upper back develop acne lesions. Therefore, it is likely that some structural differentiation predisposes a fraction of the follicles to develop acne. In most males, acne is worst in the teenage years and then subsides, suggesting that a subpopulation of follicles may be present which ultimately self-destruct. In women, teenage acne is often followed by menstrual acne flares well into adulthood. Since both plugging of the infundibulum and high sebaceous gland activity are necessary for an acne lesion to develop, it is likely that the predisposing factors for the follicles which become infected are (1) an infundibulum shape which is easily plugged, and/or (2) a hyperactive sebaceous gland. [0003]
  • Unlike medical dermatology, most laser dermatology treatments are actually “cures”—producing a permanent anatomic, microsurgical effect on the skin. This includes skin resurfacing, portwine stain treatment, tattoo and pigmented lesion removal, and hair removal. Selective photothermolysis or controlled skin ablation with lasers or other extremely intense light sources, might therefore be capable of curing skin disorders, such as acne, if appropriately targeted to the primary site(s) of pathophysiology. [0004]
  • SUMMARY OF THE INVENTION
  • The present invention is based, at least in part, on the discovery that energy activatable materials, such as chromophores, described infra, in combination with an energy source, e.g., photo (light) therapy, can be used to treat sebaceous gland disorders, e.g., eliminate, inhibit, or prevent occurrence or reoccurrence of the skin disorder. A preferred example of such a sebaceous gland disorder is acne. [0005]
  • The present invention pertains to methods for treating skin disorders associated with sebaceous follicles by topically applying an energy activatable material to a section of skin afflicted with a sebaceous gland disorder, wherein the material is activated by energy which penetrates outer layers of epidermis. A sufficient amount of the material infiltrates the afflicted section of skin and is exposed to sufficient energy to cause the material to become photochemically or photothermally activated, thereby treating the sebaceous gland disorder. In one embodiment, the sebaceous gland disorder is acne. Suitable energy sources include flash lamp based sources and lasers, such as Nd: YAG, Alexandrite, flash lamp-pumped dyes and diodes. Alternatively, the energy source can also be a continuous wave energy source. In preferred embodiments, the energy activatable material is a laser sensitive chromophore, e.g., a chromophore which is capable of being photostimulated by a laser, e.g., a dye. In a particularly preferred embodiment, the chromophore is methylene blue. [0006]
  • The present invention also pertains to methods for modifying the opening to the infundibulum by topically applying an energy activatable material to the opening to the infundibulum, wherein the material is activated by energy which penetrates outer layers of epidermis. Preferably, the perfusion of the material into the pore opening and/or sebaceous gland is increased by iontophoresis. A sufficient amount of the material infiltrates spaces about the infundibulum and the infundibulum is exposed to sufficient energy to cause the material to become photochemically or photothermally activated, thereby modifying the opening to the infundibulum. In one embodiment, the opening to the infundibulum is enlarged. In another embodiment, the opening to the infundibulum is decreased. In still another embodiment, the opening to the infundibulum is altered such that pore pluggage will not occur, e.g., the infundibulum is reshaped such that excess sebum, oils, dirt and bacteria will not cause pore pluggage to occur, resulting in a black head (comedon) or white head (milium). [0007]
  • The present invention also pertains to methods for down regulating, e.g., decreasing, the oil/lipid output production of the sebaceous gland. Application of the energy activatable material to the pilosebaceous unit, e.g., the sebaceous gland, followed by stimulation by an energy source can cause selective permanent physical alteration to the sebaceous gland and/or follicle such that surrounding tissue remains unaffected. The physical alteration to the sebaceous gland and/or follicle results in diminished production of sebum. [0008]
  • The present invention further pertains to methods for modifying the pilosebaceous unit by topically applying an energy activatable material to the pilosebaceous unit, wherein the material is activated by energy which penetrates into the dermis and into the outer layers of epidermis. A sufficient amount of the material infiltrates the pilosebaceous unit and the pilosebaceous unit is exposed to sufficient energy to cause the material to become photochemically or photothermally activated, thereby modifying the pilosebaceous unit. In one embodiment, the pilosebaceous unit is treated such that sebum production is diminished. A decrease in pore pluggage can occur, as a result of the diminishment of sebum production. In one preferred embodiment, treatment of the pilosebaceous unit by the present invention results in elimination of pore pluggage, e.g., the pilosebaceous unit is treated such that excess sebum, oils, dirt and bacteria will not cause pore pluggage to occur, resulting in a black or white head.[0009]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The file of this patent contains at least one drawing executed in color. Copies of this patent with color drawings will be provided by the Patent and Trademark Office upon request and payment of the necessary fee. [0010]
  • FIG. 1 is a cross-sectional view of hair shafts with pore pluggage and energy activatable material. [0011]
  • FIG. 2 is a cross-sectional view of a plugged follicle after an energy activatable material has been allowed to penetrate the follicle and sebaceous gland. [0012]
  • FIG. 3 is a cross-sectional view of hair shafts which include an energy activatable material during irradiation with an energy source, e.g., a laser. [0013]
  • FIGS. 4[0014] a and 4 b are cross-sectional views of hair shafts where the pore opening and infundibulum are modified by the process of the invention.
  • FIGS. 5[0015] a and 5 b are cross-sectional views of hair shafts where sebaceous glands are modified by the process of the invention.
  • FIGS. 6[0016] a and 6 b are cross-sectional views of hair shafts where debris within the pore is removed by the process of the invention.
  • FIGS. 7[0017] a and 7 b are cross-sectional views of hair shafts where the pore opening, infundibulum and sebaceous glands are modified by the process of the invention and where debris within the pore is also removed.
  • FIG. 8 depicts methylene blue which has been iontophoretically administered into the sebaceous glands and/or infundibulum of an individual. [0018]
  • FIG. 9 depicts light microscopy of blue staining of the epidermis, sebaceous glands and hair follicles. [0019]
  • FIG. 10 is a color photograph depicts light microscopy of blue staining of the epidermis, sebaceous glands and hair follicles. [0020]
  • DETAILED DESCRIPTION OF THE INVENTION
  • The features and other details of the invention will now be more particularly described and pointed out in the claims. It will be understood that the particular embodiments of the invention are shown by way of illustration and not as limitations of the invention. The principle features of this invention can be employed in various embodiments without departing from the scope of the invention. [0021]
  • The present invention is based, at least in part, on the discovery that energy activatable materials, such as chromophores, described infra, in combination with an energy source, e.g., photo (light) therapy, can be used to treat sebaceous gland disorders, e.g., eliminate, remove, or prevent occurrence or reoccurrence of the sebaceous gland disorder. Examples of such sebaceous gland disorders include sebaceous gland hyperplasia, acne vulgaris and acne rosacea. A preferred example of such a sebaceous gland disorder is acne. [0022]
  • In one aspect, the present invention is drawn to methods for treating sebaceous gland disorders by topically applying an energy activatable material to a section of skin afflicted with a sebaceous gland disorder. The energy activatable material is energetically stimulated by an energy source. For example, the energy activatable material can be a chromophore which absorbs at least one frequency band of energy which penetrates outer layers of epidermis. A sufficient amount of the material infiltrates the skin and the section of skin is exposed to at least one frequency band of energy so as to impart, to the material, sufficient energy to cause the material to become photochemically or photothermally activated which brings about a physiological change, thereby treating the sebaceous gland disorder. In one embodiment, the sebaceous gland disorder is acne. Suitable energy sources include a wide range of electromagnetic sources including, energy emitted by the sun, Rf (radio frequency) energy, energy from microwave generators, ultraviolet light generators, flash lamp based sources and lasers, such as Nd: YAG, Alexandrite, and flash lamp-pumped dyes and diodes. Alternatively, the energy source can be a continuous wave energy source. In preferred embodiments, the energy activatable material is a laser sensitive chromophore, e.g., a chromophore which is capable of being photostimulated by a laser. In a particularly preferred embodiment, the chromophore is methylene blue. [0023]
  • The present invention also pertains to methods for modifying the opening to the infundibulum by topically applying an energy activatable material to the opening to the infundibulum, wherein the material absorbs at least one frequency band of energy which penetrates outer layers of epidermis. A sufficient amount of the material infiltrates spaces about the infundibulum and the section of skin is exposed to at least one frequency band of energy so as to impart to the material, sufficient energy to cause the material to become photochemically or photothermally activated, thereby modifying the opening to the infundibulum. In one embodiment, the opening to the infundibulum is altered such that pore pluggage will not occur, e.g., the infundibulum is reshaped such that excess sebum, oils, dirt and bacteria will not cause pore pluggage to occur, resulting in a blackhead (comedon) or white head (milium). In a preferred embodiment, the opening to the infundibulum is opened. [0024]
  • The present invention further pertains to methods for modifying the pilosebaceous unit by topically applying an energy activatable material to the pilosebaceous unit, wherein the material absorbs at least one frequency band of energy which penetrates outer layers of epidermis. A sufficient amount of the material infiltrates the pilosebaceous unit and the section of skin is exposed with at least one frequency band of energy so as to impart to the material, sufficient energy to cause the material to become photochemically or photothermally activated, thereby modifying the pilosebaceous unit. In one embodiment, the pilosebaceous unit is treated such that sebum production is diminished, thereby resulting in decreased pore pluggage. In one preferred embodiment, treatment of the pilosebaceous unit by the present invention results in elimination of pore pluggage, e.g., the pilosebaceous unit is treated such that excess sebum, oils, dirt and bacteria will not cause pore pluggage to occur, resulting in a black or white head. [0025]
  • Sebaceous glands are components of the pilosebaceous unit. They are located throughout the body, especially on the face and upper trunk, and produce sebum, a lipid-rich secretion that coats the hair and the epidermal surface. Sebaceous glands are involved in the pathogenesis of several diseases, the most frequent one being acne vulgaris. Acne is a multifactorial disease characterized by the occlusion of follicles by plugs made out of abnormally shed keratinocytes of the infundibulum (upper portion of the hair follicle) in the setting of excess sebum production by hyperactive sebaceous glands. Various treatment modalities for acne exist that aim in modifying the rate of sebum secretion by the sebaceous glands (e.g., retinoids), inhibiting the bacterial overgrowth in the follicular duct (antibiotics), or decreasing the inflammation of acne lesions (anti-inflammatory agents). Most of these agents are not curative of acne and simply control the disease by affecting one of the aforementioned pathogenic factors. Oral retinoids are a notable exception: they are potent drugs that can achieve a significant cure rate for acne, but their side effect profile often limits their use. Advantages of the present invention include that treatment can permanently alter the pilosebaceous unit, rendering it no longer susceptible to pore pluggage without the side effects associated with oral retinoids. [0026]
  • The term “sebaceous gland disorders” is intended to include those sebaceous gland disorders which can be treated by an energy activatable material. The energy activatable material can be a photothermally or photochemically activatable, e.g., reactive, material which is susceptible to photoactivation or stimulation, e.g., light, i.e., laser stimulation. The activation or excitation of the material generates reactive species, such as radicals, which can interact with the site of pore pluggage, inflammation, bacteria, viruses, etc. and promote, for example, oxidation of those agents which are associated with the disorder. Examples of sebaceous gland disorders which can be treated by the methods of the invention include sebaceous gland hyperplasia, acne vulgaris and acne rosacea. Of particular importance is treatment of acne by the method of the invention. [0027]
  • The term “pluggage” is intended to obstruction of the pores by the buildup of sebum, dirt, bacteria, mites, oils, and/or cosmetics in the pore, e.g., about the infundibulum. [0028]
  • The term “acne” is art recognized and is intended to include acne vulgaris and acne rosacea. Acne vulgaris the most common skin disease seen in dermatologic practice which affects approximately 17 million people in the United States. Its precise cause is unknown, although abnormal keratin production with obstruction of the follicular opening, increased production of sebum (lipids secreted by the androgen-sensitive sebaceous glands), proliferation of [0029] Propionibacterium acnes (anaerobic follicular diphtheroids), follicular rupture and follicular mites (demodex) are commonly associated with acne.
  • Skin conditions such as acne are believed to be caused or exacerbated by excessive sebum flow produced by sebaceous glands most of which are adjacent to and discharge sebum into, hair follicles. Sebum is composed of keratin, fat, wax and cellular debris. Sebum forms a moist, oily, acidic film that is mildly antibacterial and antifungal and may to some extent protect the skin against drying. It is known that the bacteria which contribute to acne, [0030] Propionibacterium acnes or (P-acnes), grows in sebum. Significant sebum flow in humans begins at puberty. This is when acne problems generally arise.
  • The phrase “energy activatable material” is intended to include those agents which, when stimulated by energy from an energy source, e.g., a laser source, become energetically stimulated, e.g., photothermally or photochemically. These materials can be stimulated by various energy sources, e.g., electromagnetic sources, such as a continuous wave source, a laser source, flashlamp, ultraviolet light, microwaves, infrared light, etc. The material absorbs the energy which causes the material to become thermally or chemically active. [0031]
  • Suitable materials useful in the invention include metal oxides, such as aluminum oxide, iron oxides, carbon particles (graphite and amorphous carbon particles) and natural and synthetic chromophores. The term “chromophore” is art recognized and is intended to include those compounds which absorb energy at a given wavelength, often by sites of unsaturation, carbon-oxygen bonds, and/or charged species, or combinations thereof. Suitable chromophoric groups include nitro groups, azo, quinoids, alkylene units, carbonyls, esters, alkynes, aldehydes, carboxylic acids, and those groups associated with n®p* and p®p* transitions. Preferred energy activatable materials include laser sensitive dyes, for example, methylene blue, indocyanine green and those in U.S. Pat. No. 4,651,739, issued Mar. 24, 1987, the entire contents of which are incorporated herein by reference. Preferred dyes are those dyes which are activated by laser stimulation. Preferred laser sensitive dyes are those which are FDA approved. A preferred dye, a laser sensitive dye, is methylene blue. In one embodiment, the laser sensitive dye is not indocyanine green. In another embodiment, the energy activatable material is not carbon particles. [0032]
  • The energy activatable materials of the present invention undergo energetic activation, by photothermal or photochemical stimulation. The term “photothermal” interaction (excitation or stimulation) is art recognized and is intended to include interactions which are due to conversion of energy into heat. Photothermal activation of an energy activatable material causes the material to be heated, thereby heating the local area, preferably selectively with a significant temperature increase of such that unwanted material, e.g., tissues, oils, bacteria, viruses, dirt, etc. such that the surrounding tissue remains unaffected The photothermally activated material can form biologically reactive products. Photothermal processes can involve oxidation of, for example, cell walls, extracellular matrix components, nuclei, etc. As a result of photothermal stimulation, the infundibulum can be reshaped as a result of collagen shrinkage. Additionally, the process can cause cell death in the sebaceous gland, thereby decreasing production of sebum. [0033]
  • The term “photochemical” is art recognized and is intended to include molecular bond breaking where one or more absorbed photon excites the molecule to a higher electronic, vibrational, or rotational state. Photochemical stimulation of an energy activatable material causes the material to enter an excited energy state wherein energy is absorbed, e.g., by the chromophore, whereby bonds within the energy activatable material are broken and forms reactive by products such as radical species. These reactive by products can interact with the localized surrounding tissue area such that the tissue is cleansed of unwanted material, e.g., oils, bacteria, viruses, dirt, etc. As a result of photochemical stimulation, the infundibulum can be reshaped as a result of collagen shrinkage. Additionally, the photochemical process can cause cell death in the sebaceous gland, thereby decreasing production of sebum. [0034]
  • The photochemically activated material can return to the ground state or it can decompose into biologically reactive fragments. Photochemical processes can involve oxidation or radical polymerization of, for example, cell walls, extracellular matrix components, nuclei, etc. [0035]
  • Photochemical activation of energy activatable materials can be achieved over long time periods with energy of low intensity. For example, treatment of sebaceous gland disorders could be treated with an energy activatable material contained in a cream or lotion applied to the skin prior to long periods of exposure to the sunlight, e.g., while participating in sports or sitting on the beach. [0036]
  • The energy activatable materials of the present invention do not undergo fragmentation or vaporization such that the energy activatable material causes photo-mechanical destruction of the surrounding tissue, e.g., the energy activatable materials do not undergo violent decomposition, i.e., the energy activatable materials do not explode. Preferably, therefore, the energy activatable material is subjected to a sufficient energy which causes the energy activatable material to be photochemically or photothermally stimulated without violent decomposition and harm to surrounding tissue (See for example Ton G. van Leeuwen et al. Optical-Thermal Response of Laser-Irradiated Tissue, “Pulsed Laser Ablation of Soft Tissue” ed. A. J. Welch and M. J. C. van Gemert, Chapter 21, pg 709, Plenum Press, New York, 1995). [0037]
  • Not to be limited by theory, stimulation of the energy activatable material, e.g., a chromophoric agent, can cause oxidation and decomposition of the unwanted material(s), thereby degrading and removing unwanted material from the pore. Additionally, this treatment can also cause the opening to the infundibulum to become modified, e.g., the pore opening is enlarged or the pore opening is constricted or closed. Consequently, alteration of the pore opening, such as enlargement of the pore opening, a change in the pore shape, or constriction of the pore opening prevents unwanted dirt, bacteria, viruses and/or oils from building up in the treated area, e.g., the infundibulum. [0038]
  • Photothermal alteration of the sebaceous gland, the follicle infundibulum, or both requires the deposition of sufficient energy to cause local heating to temperatures capable of cell killing (e.g. killing of sebocytes, stem cells, or bacterial cells), protein denaturation (e.g., denaturation of basement membranes and/or perifollicular collagen), or vaporization of tissue. In general, these temperatures range from about 60-100[0039]
    Figure US20040006328A1-20040108-P00001
    C. for the first two effects, and somewhat over 100
    Figure US20040006328A1-20040108-P00001
    C. (e.g., about 120
    Figure US20040006328A1-20040108-P00001
    C.) for vaporization of tissue.
  • The amount of a light-absorbing dye which must be present for a given local fluence of a pulse of optical energy to cause these photothermal effects, can be determined by considering the basic principles of selective photothermolysis. If the pulse of optical radiation is delivered within the thermal relaxation time for the target structure, heat flow from the target is limited during the pulse. The preferred pulse duration is therefore about equal to or less than the thermal relaxation time of the given target, which measured in seconds is approximately equal to the square of the target's shortest dimension measured in millimeters. For example, the infundibulum portion of most sebaceous follicles on the face is approximately 0.3 mm in diameter, which corresponds approximately to a thermal relaxation time of about 0.1 seconds (100 ms). The sebaceous gland is similar in diameter, but may on the nose be as large as 1 mm. Although thermal confinement is achieved with pulses shorter than the target's thermal relaxation time, very short pulses cause unwanted mechanical injury which can rupture the follicles. For example, the method of Tankovich, U.S. Pat. Nos. 5,752,949, 5,425,728, 5,226,907 and 5,752,948, employs explosive, photomechanical mechanism to damage hair follicles. Skin eruption has been observed on patients with an acne-like skin caused by the Tankovich treatment. [0040]
  • The fatty acids, sebum, and bacteria present in sebaceous follicles is extremely irritating if not contained by the follicle. In acne vulgaris, rupture of the follicle is the event which stimulates inflammation to form a “pimple”, including accumulation of pus to form a “whitehead”. It is therefore desired to avoid rupture of the follicle or sebaceous gland. Such mechanical injury can be avoided by using pulses longer than about 0.1 milliseconds. Thus, the preferred range of pulse duration is 0.1-100 ms, and the ideal pulse duration is about 10-50 ms. [0041]
  • When thermal confinement during the pulse is achieved, the local temperature rise is given approximately by DT=Em(rc)[0042] −1, where E is the local fluence at the target, m is the local absorption coefficient of the target, and rc is heat capacity of the target. It is highly preferred to use wavelengths of the optical spectrum in which natural skin pigments exhibit weaker absorption (to minimize heating at other sites), and which penetrate well to the anatomic depth of the infundibulum and/or sebaceous glands. The orange, red, and near-infrared wavelength region (600-1200 nm) is therefore most appropriate. At these wavelengths, there is very little absorption by natural skin pigments other than melanin.
  • Melanin is often present in coarse hairs, but in general is absent or nearly absent in the vellus hairs present in the sebaceous follicles associated with acne vulgaris. The exception to this is when a “blackhead” (an open comedo) is present, which consists of a plugged sebaceous follicle containing melanin or melanin-like oxidized substances which absorb light. To a reasonable approximation, therefore, there is no optical absorption in the 600-1200 nm wavelength region in most sebaceous follicles. The tolerable fluence for human skin of an optical pulse in this part of the spectrum is about 5-100 J/cm[0043] 2, depending on the amount of epidermal melanin and on wavelength. Skin surface-cooling methods can also be used to increase this tolerable fluence. Ideally, an amount of dye can be taken up by the sebaceous follicle such that a pulse delivering less than 100 J/cm2 can produce desired photothermal effects. The target absorption coefficient, m, is approximately equal to 2.3, times the local molar concentration [d] of the dye in the follicle, times the molar extinction coefficient e for that dye. The value of rc for most tissues is about 4 Jcm−3C−1. Many dyes have molar extinction coefficients of 103-105 M−1cm−1.
  • From this information, the local dye concentration needed in the follicle can be estimated, and used to direct therapy. For example, to reach a temperature of approximately 80[0044]
    Figure US20040006328A1-20040108-P00001
    C., a temperature rise DT would be about 50
    Figure US20040006328A1-20040108-P00001
    C. because the ambient skin temperature is typically about 30
    Figure US20040006328A1-20040108-P00001
    C. At a fluence of E=10 J/cm2 (easily tolerated by most skin types), the local value of m must therefore be about m=DTrc/E=(50)(4)(10), or 20 cm−1. The concentration of a dye to achieve this absorption coefficient at the target, can be determined. Preferred dyes such as methylene blue have molar extinction coefficients about e=104 M−1cm−1, which require uptake to a dye concentration [d] in the follicle of about [d]=m/(2.3e)=20/(2.3×104), or about 10−3M.
  • Thus, about 1 mM concentration of these dyes is sufficient to achieve the desired photothermal effects to inhibit acne vulgaris. Because a factor of 10 was allowed in the tolerable fluence in the above example, it would be possible (minimally) to practice the invention with values of m as low as about 2 cm[0045] −1, corresponding to dye concentration of about 0.1 mM (100 mM). However, it is preferred in practice to provide a safety margin between the fluence necessary for the desired photothermal effect on sebaceous glands and/or infundibulum, and the maximum fluence tolerated by human skin. The preferred dye concentration in the follicle infundibulum and/or sebaceous gland is therefore greater than 0.1 mM for most of the preferred dyes, and more generally a sufficient concentration to achieve a local absorption coefficient of greater than about 10 cm−1.
  • Preferably, the energy source produces an exposure area of between about 3 to about 100 millimeters to treat a section of skin afflicted with a sebaceous gland disorder, as described above. The fluence is limited such that the skin is not damaged while the sebaceous gland disorder is treated, e.g., eradicated, inhibited, or prevented. The fluence is controlled such that localized destruction to the undesired sebaceous gland disorder occurs with little or no non-specific necrosis of surrounding tissue. For example, at 755 nm, up to 100 J/cm2 can be administered to a very fair Caucasian individual without damage to the skin. The amount of energy a darker skin could tolerate without damage to the skin would be less. A person having skill in this art can ascertain the amount of energy and type of energy to be expended to achieve the results desired. [0046]
  • Suitable energy sources include light-emitting diodes, incandescent lamps, xenon arc lamps, lasers or sunlight. Suitable examples of continuous wave apparati include, for example, diodes. Suitable flash lamps include, for example pulse dye lasers and Alexandrite lasers. Representative lasers having wavelengths strongly absorbed by chromophores, e.g., laser sensitive dyes, within the epidermis and infundibulum but not sebaceous gland, include the short-pulsed red dye laser (504 and 510 nm), the copper vapor laser (511 nm) and the Q-switched neodymium (Nd):YAG laser having a wavelength of 1064 nm that can also be frequency doubled using a potassium diphosphate crystal to produce visible green light having a wavelength of 532 nm. Further examples of lasers which are suitable for use as energy sources include those in the following table of lasers: [0047]
  • Types of Laser Commercial Laser Types, Organized by Wavelength
  • [0048]
    Wavelength, mm Type Output type and power
    0.523 Doubled Nd-YLF Pulsed, watts
    0.532 Doubled Nd-YAG Pulsed to 50 W or CW to
    watts
    0.534,0,538 He-Cd CW, milliwatts, in white-
    light laser
    0.5435 He-Ne CW, 1-mW range
    0.578 Copper vapor Pulsed, tens of watts
    400-700 nm Pulsed Dye tens of Joules
    514.5 nm Ar Ion tens of watts
    530.9 nm Kr Ion approximately 5 watts
    750-900 nm GaAIAs semiconductor tens of watts depending on
    diode array number of elements
    1060 nm Nd:YAG tens of watts
  • Another desirable property of thermal and photochemical energy activatable material is an absorption spectrum in the range of 600-1300 nm; this minimizes surrounding blood from absorbing light intended for the material (hemoglobin absorbs most strongly at the violet end of the spectrum). [0049]
  • The depth of penetration of the energy, e.g., light, emitted from the energy source, such as a laser, is dependent upon its wavelength. Wavelengths in the visible to near IR have the best penetration and are therefore best for use to treat the sebaceous gland and infundibulum located within the dermis. [0050]
  • Photochemical cell killing preferably uses chromophores with peak absorbance in the 600-1300 nm range. Whether photostability is important depends on the mechanism of photochemical cell killing. For example, chromophores which kill by the interaction with oxygen to produce singlet state oxygen, high photostability is desirable, so that such production continues for as long as possible before the chromophore breaks down. [0051]
  • For chromophores which kill by virtue of the degradation of the chromophore to a toxic reaction product, photostability is generally not desired, since the breakdown of the chromophore is the process which achieves the desired effect. [0052]
  • In the present process, selective photoactivation is employed whereby an energy (light) source, e.g., a laser, is matched with a wave-length to the absorption spectrum of the selected energy activatable material, preferably a chromophoric agent, e.g., methylene blue at 661 nm. For example, an energy activatable material, adapted to accumulate selectively in the infundibulum and/or the sebaceous gland, is first applied to the region of afflicted skin to be treated. Following absorption of the energy activatable material, the accumulated material, is exposed to an energy source, e.g., a laser, capable of producing a wavelength readily absorbed by the energy activatable material thereby selectively photothermally heating or photochemically treating those regions of the dermis known to have trapped oils, bacteria, viruses, dirt, etc. i.e., the pilosebaceous unit which includes the pore opening, infundibulum and sebaceous gland. Because the energy activatable material is selectively concentrated within or about these undesired deposits, the deposits are degraded by the heat and/or radical species generated from the energy activated material. There is minimal to no destruction of normal adjacent epidermal and dermal structures. [0053]
  • Preferably, the treatment of the invention modifies the pore opening to the infundibulum such that the geometry, e.g., the shape, of the opening is permanently altered. Adjustment of the concentration of the energy activatable material and the amount of energy applied by the energy source effects constriction, closure, or opening of the pore, thereby preventing accumulation of dirt, oils, bacteria, or viruses in that follicle. The operator will need to assess the parameters to illicit the desired effect and will be determined on a patient by patient basis. Generally, it is most desirable to alter the shape of the pore, leaving the pore enlarged and no longer prone to buildup of sebum and/or foreign materials which would cause pore pluggage. [0054]
  • As previously stated, the present invention involves the use of energy sources, e.g., lasers, to target sebaceous glands and cause their photothermal or photochemical destruction. Sebaceous glands are mainly composed of amorphous lipid material and do not contain any obvious endogenous chromophores. In order to achieve selective photocoagulation of sebaceous glands and confine the extent of thermal injury in the surrounding tissue, a topically applied energy activatable material with selective distribution to the pilosebaceous unit can be utilized. The introduction of a energy activatable material in sebaceous glands followed by exposure to energy (light) with a wavelength that corresponds to the absorption peak of the chromophore, will increase the local absorption of light in tissue and lead to selective thermal damage of sebaceous glands. [0055]
  • The infundibulum is a critical site in the pathogenesis of many of the disease states, especially acne. There is evidence that abnormal proliferation and desquamation of infundibular keratinocytes leads to the formation of microcomedones and, later on, to clinically visible follicular “plugs” or comedones. Clinically, it appears that some sebaceous follicles are more prone than others to develop acne lesions, possibly due to an inherent structural difference or functional abnormality of the infundibulum, that predisposes them to form plugs and occlude. The self-resolving nature of acne in most patients may reflect the elimination of such “acne-prone” follicles which are eventually replaced by normal skin or fibrosis after repeated bouts of inflammation. If the architecture of the infundibulum is important in the pathogenesis of acne, then selective destruction of this portion of the follicle through energy activatable material-assisted energy, e.g., laser, targeting can help eliminate or correct the “pathologic” site by creating a distended follicular opening that is able to extrude any occluded material. [0056]
  • The process of selective energy activation according to the present invention uses energy sources, e;g., light, e.g., lasers, matched to a particular energy activatable material. In the case of photothermal activation, to facilitate temperature rise, the pulse duration time period should be shorter than that of the thermal relaxation time for the energy activatable material. The thermal relaxation time is defined as the time it takes for a structure to cool to 50% of its peak temperature immediately following exposure to a light source capable of providing enough energy to photoactivate the chromophore. Therefore, selective treatment of those dermal regions containing an energy activatable material, e.g., a laser sensitive dye, will occur when exposed to millisecond light pulses. A laser delivering pulses in the range of 1 to 50 milliseconds (ms) has been found to adequately photoactivate energy activatable materials, such as carbon particles, iron oxide particles and laser sensitive dyes, e.g., chromophoric materials, deposited within the hair follicle matrix, e.g., about the infundibulum and sebaceous gland. Different types of energy activatable materials require variations in the energy dose applied and the type of energy source necessary to effect treatment of the afflicted skin area. When applied to the skin of the region to be treated, the energy activatable material is absorbed within the hair follicle matrix and upon exposure, the energy will be concentrated in those critical areas of the follicle matrix where the energy activatable material has collected e.g., the pilosebaceous unit including the sebaceous gland, infundibulum and pore opening. [0057]
  • Delivery of the energy activatable material, preferably methylene blue or other FDA approved dyes, to the follicle matrix can be achieved by topical application, injection, liposome encapsulation technology, massage, iontophoresis or ultrasonic technology, or other means for delivery of compounds into the dermal region of the skin, e.g., pharmaceutically acceptable carriers. [0058]
  • The phrase “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a energy activatable material of the present invention within or to the subject such that it can performs its intended function. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. Preferred carriers include those which are capable of entering a pore by surface action and solvent transport such that the energy activatable material is carried into or about the pore, e.g., into the sebaceous gland, to the plug, into the infundibulum and/or into the sebaceous gland and infundibulum. [0059]
  • Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening and perfuming agents, preservatives and antioxidants can also be present in the compositions. Liquid dosage forms for topical administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, creams, lotions, ointments, suspensions and syrups. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, peach, almond and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. [0060]
  • Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof. [0061]
  • The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. [0062]
  • The term “cream” is art recognized and is intended to include semi-solid emulsion systems which contain both an oil and water. Oil in water creams are water miscible and are well absorbed into the skin, Aqueous Cream BP. Water in oil (oily) creams are immiscible with water and, therefore, more difficult to remove from the skin. These creams are emollients, lubricate and moisturize, e.g., Oily Cream BP. Both systems require the addition of either a natural or a synthetic surfactant or emulsifier. [0063]
  • The term “ointment” is art recognized and is intended to include those systems which have oil or grease as their continuous phase. Ointments are semi-solid anhydrous substances and are occlusive, emollient and protective. Ointments restrict transepidermal water loss and are therefore hydrating and moisturizing. Ointments can be divided into two main groups—fatty, e.g., White soft paraffin (petrolatum, Vaseline), and water soluble, e.g., Macrogol (polyethylene glycol) Ointment BP. [0064]
  • The term “lotion” is art recognized and is intended to include those solutions typically used in dermatological applications. [0065]
  • The term “gel” is art recognized and is intended to include semi-solid permutations gelled with high molecular weight polymers, e.g., carboxypolymethylene (Carbomer BP) or methylcellulose, and can be regarded as semi-plastic aqueous lotions. They are typically non-greasy, water miscible, easy to apply and wash off, and are especially suitable for treating hairy parts of the body. [0066]
  • In a one embodiment, liposomes are used to deliver the energy activatable material to the follicle matrix. Liposomes provide site-specific transdermal delivery to the follicle matrix. In this embodiment, the energy activatable material is microencapsulated within the liposome and topically applied to the epidermis of the skin. [0067]
  • As noted above, the carrier according to the present invention involves encapsulating the effective amount of energy activatable material within a specific liposome to provide for efficient transdermal delivery of the energy activatable material through the layers of the skin. These liposomal compositions are topically applied to the skin and deliver the encapsulated energy activatable material to the follicle region including the sebaceous gland and infundibulum. Following delivery of the energy activatable material, irradiation results in highly specific targeting of the follicle matrix and destruction of oils, dirt, bacteria, mites, or viruses within the infected area. [0068]
  • Liposomes are microscopic spherical membrane-enclosed vesicles or sacks (0.5-500 mm in diameter) made artificially in the laboratory using a variety of methods. Within the scope of the present invention, the liposomes should be non-toxic to living cells and they should deliver the contents, in this case an energy activatable material, into the follicle and immediately surrounding tissue. The liposomes according to the present invention may be of various sizes and may comprise either one or several membrane layers separating the internal and external compartments. [0069]
  • The liposomes may be made from natural and synthetic phospholipids, and glycolipids and other lipids and lipid congeners; cholesterol, cholesterol derivatives and other cholesterol congeners; charged species which impart a net charge to the membrane; reactive species which can react after liposome formation to link additional molecules to the lysome membrane; and other lipid soluble compounds which have chemical or biological activities. [0070]
  • A general discussion of the liposomes and liposome technology can be found in an article entitled, “Liposomes” by Marc J. Ostro, published in [0071] SCIENTIFIC AMERICAN, January 1987, Vol. 256, pp. 102-111 and in a three volume work entitled, “Liposome Technology” edited by G. Gregorriadis, 1984, published by CRC press, Boca Raton, Fla. the pertinent portions of which are incorporated herein by reference.
  • FIG. 1 illustrates multiple hair shafts [0072] 10 (vellus) projecting below the epidermis region 12 of the skin and into the dermis 14 region. Each shaft 10 extends down the follicle 16. The follicle includes a sebaceous gland 20 and which at the anagen stage of the hair cycle further includes a papilla 18. The papilla 18 is supplied with small blood vessels (not shown) that provide the growing hair with nourishment. The follicle 16 includes the pore opening 22 and the infundibulum 24, shown with a plug 26 of dead cells, oils, bacteria and/or viruses. Topical application of an energy activatable material 28 penetrates the pore opening 22 and infundibulum 24 and into the sebaceous gland 20 as shown in FIGS. 1 and 2.
  • In order to assure removal of plug [0073] 26, modification of pore opening 22, modification of the infundibulum 24, and/or modification of the sebaceous gland 20, use of a light source, e.g., a laser, having sufficient energy and depth of penetration is required. FIG. 3 demonstrates how an operator (not shown) will position the energy source 30, e.g., a laser, over a hair follicle 16 such that an optimum location for aiming the light pulse to strike the energy activatable material 28 about the plug 26, sebaceous gland 20, infundibulum 24 and/or pore opening 22 is obtained. The energy source 30 can be moved across the skin surface in any direction 32 by the operator, thereby effectively irradiating multiple follicles 16 multiple times. The process can be repeated until the desired effect(s) are achieved.
  • FIGS. 4[0074] a and 4 b demonstrate the effect(s) of the presently described treatment on the infundibulum 24. FIG. 4a depicts infundibulum 24 prior to treatment with an energy activatable material 28 and stimulation with an energy source 30. FIG. 4b depicts the same infundibulum 24 post treatment whereby the shape of the infundibulum 24 and pore opening 22 have been modified.
  • FIGS. 5[0075] a and 5 b demonstrate the effect(s) of the presently described treatment on the sebaceous gland 20. FIG. 5a depicts the sebaceous gland 20 prior to treatment with an energy activatable material 28 and stimulation with an energy source 30. FIG. 5b depicts the same sebaceous gland 20 post treatment, whereby the size of sebaceous gland 20 has been decreased.
  • FIGS. 6[0076] a and 6 b demonstrate the effect(s) of the presently described treatment on a plugged pore 26. FIG. 6a depicts the plug 26 prior to treatment with an energy activatable material 28 and stimulation with an energy source 30. FIG. 6b depicts the same region of the infundibulum 24 post treatment, whereby the plug 26 has been treated such that unwanted material(s) has been removed from infundibulum 24.
  • FIGS. 7[0077] a and 7 b further demonstrate the effect(s) of the presently described treatment on a plugged pore 26, infundibulum 24, pore opening 22, and sebaceous gland 20. FIG. 7a depicts the skin area prior to treatment with an energy activatable material 28 and stimulation with an energy source 30. FIG. 7b depicts the same region of the skin post treatment, whereby the plug 26 has been treated such that unwanted material(s) has been removed from infundibulum 24 and the infundibulum 24, pore opening 22 and sebaceous gland 20 have been modified.
  • Stimulation of the energy activatable material [0078] 28 will cause activation to occur, e.g., photothermolysis and/or photochemical reactions, to disrupt the trapped cells, sebum, bacteria, mites, etc. located in the sebaceous gland 20 and/or the infundibulum 24. An advantage of this process is that only tissue having energy activatable material will undergo photothermal or photochemical reactions. Surrounding tissue which does not include energy activatable material will not be adversely affected by this treatment.
  • Natural chromophores present in sebaceous follicles or follicular plugs are not sufficiently distinct from other chromophores of the dermis and epidermis to allow specific absorption. However, the infundibulum and sebaceous glands are directly accessible from the skin surface through a “pore” (the follicle opening), which allows topically-applied substances, such as energy activatable materials, to enter these structures. Therefore, energy activatable materials or particle-suspensions can be used to provide high, local, and specific absorption after uptake into the infundibulum and/or sebaceous gland. [0079]
  • Energy activatable materials which enter the sebaceous follicles, such as methylene blue (a lipophilic, cationic, FDA-approved dye is taken up into human sebaceous follicles, and distributed over time into the sebaceous glands), can be used to target either the infundibula, or the sebaceous glands depending on time after application, or both. [0080]
  • Topically-applied energy activatable materials initially enter the infundibulum and later distribute to the sebaceous glands. It is possible to actively drive those materials or chromophoric particles into the follicles by massage, pressure, ultrasound, or iontophoresis, after topically applying the chromophore to the skin surface. Methylene blue, for example, can be rapidly driven into sebaceous follicles and eccrine sweat ducts by iontophoresis. Wiping the surface with or without a solvent after delivery into the follicles, can be used to remove residual material from the skin surface. Thus, after appropriate application and wiping, the energy activatable material, e.g., a chromophore, can be preferentially located in follicles, within the infundibula or the infundibula and sebaceous glands. [0081]
  • A preferred method of delivery for administering an energy activatable material described throughout this application is by iontophoresis. Iontophoresis may be generally described as a method of transdermally introducing medicament ions, zwitterions, molecules, e.g., an energy activatable material, preferably methylene blue, into a the body. The iontophoresis process utilizes the current developed by an electric field to drive energy activatable ions through the skin, or other biological surface, and into the body. The iontophoresis process has been found to be particularly useful in transdermal administration of energy activatable materials, such as many of the compounds discussed herein, and in particular, methylene blue. [0082]
  • For example, and advantage of iontophoresis is the introduction of energy activatable materials directly into a patient's tissues, e.g., the infundibulum and/or sebaceous gland, without the need for a needle-based injection, which typically causes pain and may create a risk of infection. Iontophoretic delivery of energy activatable materials is also advantageous because this delivery system avoids premature metabolism of the material that can typically occur when a drugs is taken orally. Premature metabolism is often a concern where oral drugs are used to treat acne because the medicament ions derived are absorbed into the blood stream from the digestive system. The blood containing the medicament ions then percolates through the liver, where the medicament ions may be prematurely metabolized, before the medicament ions arrive at the target tissue. Thus, a substantial amount of the medicament ions derived from an orally administered drug may be metabolically inactivated before the medicament ions have a chance to pharmacologically act in the body. [0083]
  • A typical iontophoresis device includes two electrodes such as those devices produced by Iomed, Inc. (Salt Lake City, Utah, U.S.). One of the electrodes is often characterized as an “active” electrode, and the other electrode is often characterized as a “return” electrode. Also, one of the electrodes is a positively charged anode and the other electrode is a negatively charged cathode. Both electrodes are in intimate electrical contact with the skin or other biological surface of the body, which may be a human body or another type of body, such as an animal body. Application of electric current to the active electrode drives the energy activatable material, such as the methylene blue, from the active electrode into the body. The other electrode, the return electrode, closes the electrical circuit to permit current flow through the active electrode and through the body. [0084]
  • In general, an energy activatable material is applied topically to the area to be treated as a solution or suspension. Typical solutions are aqueous based solutions, e.g., water, which can contain low molecular weight alcohols, e.g., ethanol, isopropanol, butanol. Penetration of the energy activatable material into the infundibulum and/or sebaceous gland is facilitated by iontophoretic application. Generally, the site of treatment and a major muscle site are cleansed with an alcoholic solution. A dispersive pad is applied over the major muscle at least 6 inches from the drug electrode site. A hydrated drug electrode pad is applied to the cleansed treatment site and appropriate lead clips are attached to the pads. Typically, the iontophoresis current is between about 0.1 to 40 mA/min, with a current of about 2 to 4 mA. The treatment period is generally between about 10 and 20 minutes and the treatment site can be from about 1 centimeter to about 11 centimeters in diameter. Those skilled in the art can identify those parameters necessary to administer the activatable material dependent upon the age, sex, weight, and skin condition of the individual. Energy activatable material concentrations are greatest in the infundibulum, ecrine ducts and sebaceous glands. Consequently, these structures are most affected by subsequent laser treatment. FIG. 8 depicts methylene blue which has been iontophoretically administered into the sebaceous glands and/or infundibulum of an individual. [0085]
  • As used herein, the term “iontophoresis device” refers generally to an electrically assisted device or apparatus suitable for the transdermal iontophoretic delivery of therapeutic levels of an energy activatable material to a mammal. Such iontophoresis devices are well known in the art and are also referred to as “iontophoretic delivery devices” or “electrotransport devices.”[0086]
  • Iontophoresis devices and methods for using these devices in conjunction with the present invention are described, for example, in the following U.S. patent documents, the disclosures of which are incorporated herein by reference: [0087]
  • U.S. Pat. Nos. 3,991,755; 4,141,359; 4,250,878; 4,395,545; 4,744,787; 4,747,819; 4,927,408; 5,080,646; 5,084,006; 5,125,894; 5,135,477; 5,135,480; 5,147,296; 5,147,297; 5,158,537; 5,162,042; 5,162,043; 5,167,616; 5,169,382; 5,169,383; 5,415,628; 5,203,768; 5,207,752; 5,221,254; 5,232,438; 5,234,992; 5,240,995; 5,246,417; 5,288,389; 5,298,017; 5,310,404; 5,312,326; 5,314,502; 5,320,598; 5,322,502; 5,326,341; 5,344,394; 5,374,242; 5,380,271; 5,385,543; 5,387,189; 5,395,310; 5,403,275; 5,405,317; 5,415,628; 5,423,739; 5,443,442; 5,445,606; 5,445,609; 5,464,387; 5,466,217; 4,950,229; 5,246,418; 5,256,137; 5,284,471; 5,302,172; 5,306,235; 5,310,403; 5,320,597; 5,458,569; 5,498,235; 4,557,723; 4,713,050; 4,865,582; 4,752,285; 5,087,242; 5,236,412; 5,281,287. [0088]
  • Either photothermal (i.e. using principles of selective photothermolysis) or photochemical (i.e., using principles of photodynamic therapy) mechanisms are utilized to affect the target structures, as a treatment to prevent sebaceous gland disorders, such as acne lesions, from forming. Methylene blue (MB) and many other light sensitive chromophores are potent photodynamic photosensitizers and can also be used as photothermal sensitizers. The red absorption maximum of methylene blue around 660 nm provides strong absorption for either mechanism. Another strong candidate dye is indocyanine green (ICG) (Cardiogreen®, Becton-Dickenson), which has very poor photodynamic activity but is an excellent photothermal chromophore. Indocyanine green is a zwitterion (neutral, highly polar molecule) which tends to bind strongly to proteins and is well suited for targeting the infundibulum by photothermal mechanisms. ICG absorbs maximally near 800 nm, a wavelength well suited for diode, Alexandrite lasers, and other light sources. For selective photothermolysis, pulses of intense red or near-infrared light in the ms time domain at the appropriate wavelength region should be delivered, for example using a pulsed dye laser, diode laser arrays, other pulsed or scanned lasers, or filtered flashlamp sources to deliver fluences in excess of 1 J/cm2 per pulse. For photodynamic effects, lower average irradiance exposures given over longer exposure time would be appropriate for example approximately 10-100 mW/cm2 delivered for about 100-2000 seconds (total fluence, 1-200 J/cm2). For photodynamic effect, light sources such as light-emitting diodes, incandescent lamps, xenon arc lamps, lasers or sunlight can be used. [0089]
  • In order to form and retain a plug within the infundibulum, there must be a constriction along the outflow tract. As material including sebum, cells, or bacteria accumulate and are concentrated onto the plug, walls of the infundibulum are dilated until the middle or lower part of the infundibulum is larger in diameter than its outlet (the surface pore). If the outlet diameter can be increased, the plug is more likely to be expelled and pressure within the sebaceous follicle decreased before rupture can occur. The upper region of the infundibulum is also the source of follicular neck cells which shed into the infundibulum and add to the plug. For these reasons, the walls of the upper portion of the infundibulum and especially its pore at the skin surface are the primary target for energy activatable material-assisted sebaceous gland disorder treatment, e.g. acne treatment. In a manner conceptually similar to laser skin “resurfacing”, the shape and size of the infundibulum and its outlet pore can be affected by energy activatable material-assisted photothermal or photochemical treatment. The dermis immediately surrounding sebaceous follicles, is largely responsible for maintaining shape of the infundibulum, and should be altered to produce a permanent affect. By using pulses in the ms time domain, there is time for thermal conduction from energy activatable material in the infundibulum, to the wall and immediately-surrounding dermal collagen of the infundibulum. Photothermal mechanisms are preferred because permanent changes are known to be induced in the dermis. [0090]
  • The invention is further illustrated by the following examples which in no way should be construed as being further limiting. The contents of all references, pending patent applications and published patent applications, cited throughout this application, including those referenced in the background section, are hereby incorporated by reference. It should be understood that the models used throughout the examples are accepted models and that the demonstration of efficacy in these models is predictive of efficacy in humans. [0091]
  • Exemplification
  • Fresh, in-vitro human sebaceous skin samples were used. Dye solutions and particle suspensions were applied to the samples at different concentration and in various vehicles, followed by localization of the dye by frozen sectioning and light microscopy. A number of FDA-approved laser sensitive dyes were examined and found that methylene blue and several others rapidly enter the infundibulum. Methylene blue proceeded to deeply and selectively stain the sebaceous glands, requiring several hours to do so. Apparently, almost any dye or suspension can be delivered to the upper infundibulum by direct solvent flow into the pore. Optimization of the concentration and solvent for MB and ICG can be determined by one skilled in the art. The effect of iontophoresis of MB in vitro should increase rate of uptake by at least one order of magnitude. Physical means of increasing dye uptake into the infundibulum, including ultrasonication with a tissue dismembranator at low intensity, and a simple pressure-applicator intended to open the surface pores while providing a pressure gradient in favor of dye uptake is possible. [0092]
  • For MB dye, a 660 nm source is required, preferably a pulsed dye laser operating with at least 1 ms pulse duration. There is essentially no absorption by MB at wavelengths longer than 690 nm, such that ruby and Alexandrite lasers are not useful. Similar in-vitro laser targeting can be performed using ICG in the infundibulum, and C-particle suspension (medical grade India Ink) to indicate that physical means deliver sufficient chromophore into the infundibulum. [0093]
  • Experimentals Experiment Using Methylene Blue to Stain Sebaceous Glands in Ex vivo Tissue
  • Freshly excised human skin from a face-lift procedure was provided by a plastic surgeon. The skin originated from the periauricular area and the anterior hairline of a middle-aged fair-skinned female. The samples were stored at 4[0094]
    Figure US20040006328A1-20040108-P00001
    C. overnight. On the day of experiment, the tissue was shaved with a razor and defatted by rubbing the surface with alcohol swabs for 1 minute. After cutting the skin in smaller pieces, the tissue was placed on saline-soaked gauzes. Methylene blue, a cationic hydrophilic dye was dissolved in distilled water, alcohol, and propylene glycol at a concentration of 5% and applied on the surface of the skin in a thick layer at 31
    Figure US20040006328A1-20040108-P00001
    C. After 1 hour, the excess dye was removed with a dry absorbing gauze revealing a lightly stained epidermis with accentuation of the staining in the follicular pores in all specimen. 5 mm-punch biopsies were performed and the samples were processed frozen sections.
  • Light microscopy of histologic sections showed dense blue staining of the epidermis and of some sebaceous glands and entire hair follicles (FIG. 9). There was minimal non-specific staining of the interstitial dermis. [0095]
  • Freshly excised human skin from a face-lift procedure was provided by a plastic surgeon. The skin originated from the periauricular area and the anterior hairline of a middle-aged fair-skinned female. The samples were stored at 4[0096]
    Figure US20040006328A1-20040108-P00001
    C. overnight. On the day of experiment, the tissue was shaved with a razor and defatted by rubbing the surface with alcohol swabs for 1 minute. After cutting the skin in smaller pieces, the tissue was placed on saline-soaked gauzes. Methylene blue, a cationic hydrophilic dye was dissolved in distilled water, alcohol, and propylene glycol at a concentration of 5% and was mixed in a commercially available aqueous-based lotion (50 mL of dissolved dye in 500 mg of lotion) and applied on the surface of the skin in a thick layer at 31
    Figure US20040006328A1-20040108-P00001
    C. After 1 hour, the excess dye was removed with a dry absorbing gauze revealing a lightly stained epidermis with accentuation of the staining in the follicular pores in all specimen. 5 mm-punch biopsies were performed and the samples were processed frozen sections.
  • Light microscopy of histologic sections showed dense blue staining of the epidermis and of some sebaceous glands and entire hair follicles (FIG. 10). There was minimal non-specific staining of the interstitial dermis. [0097]
  • Methylene blue dye was also administered into the sebaceous glands via Retina Gel® (Ortho Pharmaceuticals) as the carrier vehicle. Typically, a sufficient amount of methylene blue (50 mL of dissolved dye in 500 mg of gel) was combined with hydroxypropyl cellulose, butylated hydroxytoluene and alcohol and applied to the epidermis. Penetration of the methylene blue dye into the sebaceous glands of freshly excised human skin was noted via light microscopy as described above. [0098]
  • Equivalents
  • Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims. [0099]

Claims (8)

What is claimed is:
1. A method for treating a sebaceous gland disorder comprising the steps of
a) topically applying an energy activatable material to a section of skin afflicted with a sebaceous gland disorder, wherein said material is activated by energy which penetrates outer layers of epidermis,
b) iontophoretically causing a sufficient amount of said material to infiltrate into spaces in said skin; and
c) exposing said section of skin to energy sufficient to cause said material to become photochemically or photothermally activated, thereby treating said sebaceous gland disorder.
2. The method of claim 1, wherein said energy activatable material is selected from the group consisting of chromophore containing groups, carbon particles and iron oxides.
3. The method of claim 1, wherein said chromophore containing group is methylene blue.
4. The method of claim 1, wherein said chromophore containing group is a laser sensitive material.
5. The method of claim 4, wherein said laser sensitive material is methylene blue.
6. The method of claim 1, wherein said energy activatable material is suspended in a pharmaceutical carrier.
7. A method for modifying the opening to the infundibulum comprising the steps of:
a) topically applying an energy activatable material to the opening to the infundibulum, wherein said material is activated by energy which penetrates outer layers of epidermis,
b) iontophoretically causing a sufficient amount of said material to infiltrate into spaces about said infundibulum; and
c) exposing said section of skin with sufficient energy to cause said material to become photochemically or photothermally activated, thereby modifying said opening to the infundibulum.
8. A method for modifying the pilosebaceous unit comprising the steps of:
a) topically applying an energy activatable material to the pilosebaceous unit, wherein said material is activated by energy which penetrates outer layers of epidermis,
b) iontophoretically causing a sufficient amount of said material to infiltrate the pilosebaceous unit; and
c) exposing said section of skin with sufficient energy to cause said material to become photochemically or photothermally activated, thereby modifying the pilosebaceous unit.
US10/612,599 1999-01-04 2003-07-02 Targeting of sebaceous follicles as a treatment of sebaceous gland disorders Abandoned US20040006328A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/225,026 US6183773B1 (en) 1999-01-04 1999-01-04 Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
US09/464,137 US6600951B1 (en) 1999-01-04 1999-12-16 Targeting of sebaceous follicles as a Treatment of sebaceous gland disorders
US10/612,599 US20040006328A1 (en) 1999-01-04 2003-07-02 Targeting of sebaceous follicles as a treatment of sebaceous gland disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/612,599 US20040006328A1 (en) 1999-01-04 2003-07-02 Targeting of sebaceous follicles as a treatment of sebaceous gland disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/464,137 Continuation US6600951B1 (en) 1999-01-04 1999-12-16 Targeting of sebaceous follicles as a Treatment of sebaceous gland disorders

Publications (1)

Publication Number Publication Date
US20040006328A1 true US20040006328A1 (en) 2004-01-08

Family

ID=22843211

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/225,026 Expired - Lifetime US6183773B1 (en) 1999-01-04 1999-01-04 Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
US09/464,137 Expired - Lifetime US6600951B1 (en) 1999-01-04 1999-12-16 Targeting of sebaceous follicles as a Treatment of sebaceous gland disorders
US10/612,599 Abandoned US20040006328A1 (en) 1999-01-04 2003-07-02 Targeting of sebaceous follicles as a treatment of sebaceous gland disorders

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/225,026 Expired - Lifetime US6183773B1 (en) 1999-01-04 1999-01-04 Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
US09/464,137 Expired - Lifetime US6600951B1 (en) 1999-01-04 1999-12-16 Targeting of sebaceous follicles as a Treatment of sebaceous gland disorders

Country Status (6)

Country Link
US (3) US6183773B1 (en)
EP (1) EP1140180B1 (en)
CA (1) CA2360202C (en)
DK (1) DK1140180T3 (en)
ES (1) ES2539794T3 (en)
WO (1) WO2000040266A2 (en)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040167499A1 (en) * 2003-02-25 2004-08-26 Grove Robert E. Eye-safe dermatologic treatment apparatus and method
US20040167502A1 (en) * 2003-02-25 2004-08-26 Weckwerth Mark V. Optical sensor and method for identifying the presence of skin
US20040167500A1 (en) * 2003-02-25 2004-08-26 Weckwerth Mark V. Self-contained, diode-laser-based dermatologic treatment apparatus and method
US20040176823A1 (en) * 2003-02-25 2004-09-09 Island Tobin C. Acne treatment device and method
US20040176754A1 (en) * 2003-03-06 2004-09-09 Island Tobin C. Method and device for sensing skin contact
WO2005004984A1 (en) * 2003-07-14 2005-01-20 Power Paper Ltd. Device and method for the treatment of pilosebaceous disorders
US20070198071A1 (en) * 2006-02-22 2007-08-23 Juniper Medical Systems Cooling device for removing heat from subcutaneous lipid-rich cells
US20070255362A1 (en) * 2006-04-28 2007-11-01 Juniper Medical, Inc. Cryoprotectant for use with a cooling device for improved cooling of subcutaneous lipid-rich cells
US20080027518A1 (en) * 2003-02-25 2008-01-31 Spectragenics, Inc. Self-contained, eye-safe hair-regrowth-inhibition apparatus and method
US20080077202A1 (en) * 2006-09-26 2008-03-27 Juniper Medical, Inc. Tissue Treatment Methods
US20080077201A1 (en) * 2006-09-26 2008-03-27 Juniper Medical, Inc. Cooling devices with flexible sensors
US20080077211A1 (en) * 2006-09-26 2008-03-27 Juniper Medical, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
WO2008052198A2 (en) * 2006-10-26 2008-05-02 Reliant Technologies, Inc. Methods of increasing skin permeability by treatment with electromagnetic radiation
US20080287839A1 (en) * 2007-05-18 2008-11-20 Juniper Medical, Inc. Method of enhanced removal of heat from subcutaneous lipid-rich cells and treatment apparatus having an actuator
US20090018623A1 (en) * 2007-07-13 2009-01-15 Juniper Medical, Inc. System for treating lipid-rich regions
US20090018624A1 (en) * 2007-07-13 2009-01-15 Juniper Medical, Inc. Limiting use of disposable system patient protection devices
US20090018626A1 (en) * 2007-07-13 2009-01-15 Juniper Medical, Inc. User interfaces for a system that removes heat from lipid-rich regions
US20090018625A1 (en) * 2007-07-13 2009-01-15 Juniper Medical, Inc. Managing system temperature to remove heat from lipid-rich regions
US20090043294A1 (en) * 2003-02-25 2009-02-12 Spectragenics, Inc. Capacitive Sensing Method and Device for Detecting Skin
US20090204109A1 (en) * 2003-02-25 2009-08-13 Tria Beauty, Inc. Eye-Safe Dermatologic Treatment Apparatus and Method
US20090270848A1 (en) * 2008-04-25 2009-10-29 Tria Beauty, Inc. Optical Sensor and Method for Identifying the Presence of Skin and the Pigmentation of Skin
US20100081971A1 (en) * 2008-09-25 2010-04-01 Allison John W Treatment planning systems and methods for body contouring applications
US20100152824A1 (en) * 2008-12-17 2010-06-17 Allison John W Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells
US20100280582A1 (en) * 2009-04-30 2010-11-04 Zeltiq Aesthetics, Inc. Device, system and method of removing heat from subcutaneous lipid-rich cells
US20110034855A1 (en) * 2009-06-23 2011-02-10 Board Of Regents, The University Of Texas System Noninvasive therapies in the absence or presence of exogenous particulate agents
US20110066127A1 (en) * 2008-03-31 2011-03-17 Seiichi Kuwano Disposable absorbent wearing article
US7981111B2 (en) 2003-02-25 2011-07-19 Tria Beauty, Inc. Method and apparatus for the treatment of benign pigmented lesions
US20110238050A1 (en) * 2010-01-25 2011-09-29 Zeltiq Aesthetics, Inc. Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants, and associates devices, systems and methods
US8285390B2 (en) 2007-08-21 2012-10-09 Zeltiq Aesthetics, Inc. Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
US20140012163A1 (en) * 2010-08-27 2014-01-09 Sienna Labs, Inc. Thermal Treatment of Acne with Nanoparticles
US8676338B2 (en) 2010-07-20 2014-03-18 Zeltiq Aesthetics, Inc. Combined modality treatment systems, methods and apparatus for body contouring applications
US8777935B2 (en) 2004-02-25 2014-07-15 Tria Beauty, Inc. Optical sensor and method for identifying the presence of skin
US9108045B2 (en) 2007-06-27 2015-08-18 The General Hospital Corporation Method and apparatus for optical inhibition of photodynamic therapy
US9212294B2 (en) 2012-10-11 2015-12-15 Nanocomposix, Inc. Silver nanoplate compositions and methods
US9333258B2 (en) 2012-05-08 2016-05-10 The Regents Of The University Of California Fine spatiotemporal control of fat removal using NIR light
US9522289B2 (en) 2012-05-08 2016-12-20 The Regents Of The University Of California Selective fat removal using photothermal heating
US9545523B2 (en) 2013-03-14 2017-01-17 Zeltiq Aesthetics, Inc. Multi-modality treatment systems, methods and apparatus for altering subcutaneous lipid-rich tissue
USD777338S1 (en) 2014-03-20 2017-01-24 Zeltiq Aesthetics, Inc. Cryotherapy applicator for cooling tissue
US9572880B2 (en) 2010-08-27 2017-02-21 Sienna Biopharmaceuticals, Inc. Ultrasound delivery of nanoparticles
US9687508B2 (en) 2009-05-26 2017-06-27 The General Hospital Corporation Methods for alleviating acne and methods for treating a sebaceous gland
WO2017176380A1 (en) * 2016-02-22 2017-10-12 The General Hospital Corporation Systems and methods for selective targeting of structural features in treating skin conditions
US9844460B2 (en) 2013-03-14 2017-12-19 Zeltiq Aesthetics, Inc. Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same
US9861421B2 (en) 2014-01-31 2018-01-09 Zeltiq Aesthetics, Inc. Compositions, treatment systems and methods for improved cooling of lipid-rich tissue

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7006874B2 (en) * 1996-01-05 2006-02-28 Thermage, Inc. Treatment apparatus with electromagnetic energy delivery device and non-volatile memory
US7229436B2 (en) * 1996-01-05 2007-06-12 Thermage, Inc. Method and kit for treatment of tissue
US7267675B2 (en) * 1996-01-05 2007-09-11 Thermage, Inc. RF device with thermo-electric cooler
US20030212393A1 (en) * 1996-01-05 2003-11-13 Knowlton Edward W. Handpiece with RF electrode and non-volatile memory
US7473251B2 (en) * 1996-01-05 2009-01-06 Thermage, Inc. Methods for creating tissue effect utilizing electromagnetic energy and a reverse thermal gradient
US20040000316A1 (en) * 1996-01-05 2004-01-01 Knowlton Edward W. Methods for creating tissue effect utilizing electromagnetic energy and a reverse thermal gradient
US7115123B2 (en) * 1996-01-05 2006-10-03 Thermage, Inc. Handpiece with electrode and non-volatile memory
CN1617689A (en) * 1999-06-30 2005-05-18 塞梅格公司 Fluid delivery apparatus
US5871479A (en) * 1996-11-07 1999-02-16 Cynosure, Inc. Alexandrite laser system for hair removal and method therefor
US20060149343A1 (en) * 1996-12-02 2006-07-06 Palomar Medical Technologies, Inc. Cooling system for a photocosmetic device
US6508813B1 (en) 1996-12-02 2003-01-21 Palomar Medical Technologies, Inc. System for electromagnetic radiation dermatology and head for use therewith
US7135033B2 (en) 2002-05-23 2006-11-14 Palomar Medical Technologies, Inc. Phototreatment device for use with coolants and topical substances
US8182473B2 (en) * 1999-01-08 2012-05-22 Palomar Medical Technologies Cooling system for a photocosmetic device
JP4056091B2 (en) 1997-05-15 2008-03-05 ザ ジェネラル ホスピタル コーポレーション Dermatology treatment method and apparatus
US6517532B1 (en) * 1997-05-15 2003-02-11 Palomar Medical Technologies, Inc. Light energy delivery head
US6104959A (en) 1997-07-31 2000-08-15 Microwave Medical Corp. Method and apparatus for treating subcutaneous histological features
US20020169442A1 (en) * 1997-08-12 2002-11-14 Joseph Neev Device and a method for treating skin conditions
US6050943A (en) 1997-10-14 2000-04-18 Guided Therapy Systems, Inc. Imaging, therapy, and temperature monitoring ultrasonic system
US7494488B2 (en) * 1998-05-28 2009-02-24 Pearl Technology Holdings, Llc Facial tissue strengthening and tightening device and methods
US6059820A (en) 1998-10-16 2000-05-09 Paradigm Medical Corporation Tissue cooling rod for laser surgery
USRE46208E1 (en) 1998-10-16 2016-11-22 Reliant Technologies, Llc Method for cryogenically treating tissue below the skin surface
US20130274837A1 (en) * 1998-10-23 2013-10-17 Babak Nemati Systems and Methods to Enhance Optical Transparency of Biological Tissues for Photobiomodulation
US6219575B1 (en) * 1998-10-23 2001-04-17 Babak Nemati Method and apparatus to enhance optical transparency of biological tissues
US6283956B1 (en) * 1998-11-30 2001-09-04 David H. McDaniels Reduction, elimination, or stimulation of hair growth
KR20040048888A (en) * 2001-08-22 2004-06-10 라이트 바이오사이언스 인코포레이티드 Method and apparatus for acne treatment
US9192780B2 (en) * 1998-11-30 2015-11-24 L'oreal Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders
US6887260B1 (en) 1998-11-30 2005-05-03 Light Bioscience, Llc Method and apparatus for acne treatment
US6936044B2 (en) * 1998-11-30 2005-08-30 Light Bioscience, Llc Method and apparatus for the stimulation of hair growth
US20060212025A1 (en) * 1998-11-30 2006-09-21 Light Bioscience, Llc Method and apparatus for acne treatment
US6183773B1 (en) * 1999-01-04 2001-02-06 The General Hospital Corporation Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
US20020156471A1 (en) * 1999-03-09 2002-10-24 Stern Roger A. Method for treatment of tissue
US7141049B2 (en) * 1999-03-09 2006-11-28 Thermage, Inc. Handpiece for treatment of tissue
US20050055055A1 (en) * 1999-04-13 2005-03-10 Joseph Neev Method for treating acne
US6408212B1 (en) * 1999-04-13 2002-06-18 Joseph Neev Method for treating acne
WO2000064537A1 (en) * 1999-04-27 2000-11-02 The General Hospital Corporation Doing Business As Massachusetts General Hospital Phototherapy method for treatment of acne
US6358242B1 (en) * 1999-11-12 2002-03-19 Ceramoptec Industries, Inc. Post laser treatment for permanent hair removal
US20020091377A1 (en) * 2000-01-25 2002-07-11 Anderson R. Rox Method and apparatus for medical treatment utilizing long duration electromagnetic radiation
EP1263447B1 (en) 2000-02-08 2013-06-26 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
JP2004506005A (en) * 2000-08-16 2004-02-26 ザ ジェネラル ホスピタル コーポレイション ディー ビー エイ マサチューセッツ ジェネラル ホスピタル Topical aminolevulinic acid for acne vulgaris - photodynamic therapy
US20080183162A1 (en) * 2000-12-28 2008-07-31 Palomar Medical Technologies, Inc. Methods And Devices For Fractional Ablation Of Tissue
US7914453B2 (en) 2000-12-28 2011-03-29 Ardent Sound, Inc. Visual imaging system for ultrasonic probe
CN101194855B (en) * 2000-12-28 2013-02-27 帕洛玛医疗技术有限公司 Methods and products for producing lattices of EMR-treated islets in tissues, and uses therefor
US6888319B2 (en) * 2001-03-01 2005-05-03 Palomar Medical Technologies, Inc. Flashlamp drive circuit
CA2439882A1 (en) * 2001-03-02 2002-09-12 Palomar Medical Technologies, Inc. Apparatus and method for photocosmetic and photodermatological treatment
KR100699759B1 (en) * 2001-06-27 2007-03-27 라디언시 인크. Acne treatment
US7018396B2 (en) * 2001-08-07 2006-03-28 New England Medical Center Hospitals, Inc. Method of treating acne
US20040147984A1 (en) * 2001-11-29 2004-07-29 Palomar Medical Technologies, Inc. Methods and apparatus for delivering low power optical treatments
US20050021012A1 (en) * 2001-12-12 2005-01-27 Bernstein Eric F Laser treatment for reducing wrinkles
US20040082940A1 (en) * 2002-10-22 2004-04-29 Michael Black Dermatological apparatus and method
US20030216719A1 (en) * 2001-12-12 2003-11-20 Len Debenedictis Method and apparatus for treating skin using patterns of optical energy
WO2003057059A1 (en) * 2001-12-27 2003-07-17 Palomar Medical Technologies, Inc. Method and apparatus for improved vascular related treatment
US7494502B2 (en) * 2002-02-11 2009-02-24 Keraderm, Llc Alteration of the skin and nail for the prevention and treatment of skin and nail infections
US6960201B2 (en) 2002-02-11 2005-11-01 Quanticum, Llc Method for the prevention and treatment of skin and nail infections
US6913615B2 (en) * 2002-03-25 2005-07-05 Lumerx, Inc. Chemiluminescent treatment of acne
US20040039242A1 (en) * 2002-04-02 2004-02-26 Seedling Enterprises, Llc Apparatus and methods using visible light for debilitating and/or killing microorganisms within the body
WO2003089063A1 (en) * 2002-04-16 2003-10-30 Lumerx, Inc Chemiluminescent light source using visible light for biotherapy
US7351252B2 (en) * 2002-06-19 2008-04-01 Palomar Medical Technologies, Inc. Method and apparatus for photothermal treatment of tissue at depth
BR0312430A (en) 2002-06-19 2005-04-26 Palomar Medical Tech Inc Method and apparatus for treating cutaneous and subcutaneous conditions
JP2006511275A (en) * 2002-12-20 2006-04-06 パロマー・メディカル・テクノロジーズ・インコーポレイテッドPalomar Medical Technologies,Inc. Phototherapy device acne and other follicle disorders
US7703458B2 (en) * 2003-02-21 2010-04-27 Cutera, Inc. Methods and devices for non-ablative laser treatment of dermatologic conditions
US20100069898A1 (en) * 2003-02-25 2010-03-18 Tria Beauty, Inc. Acne Treatment Method, System and Device
US20040176824A1 (en) * 2003-03-04 2004-09-09 Weckwerth Mark V. Method and apparatus for the repigmentation of human skin
DE202004021226U1 (en) 2003-03-27 2007-07-26 The General Hospital Corp., Boston Device for dermatological treatment and fractional resurfacing the skin
EP1617777A4 (en) * 2003-04-10 2010-11-03 Gentlewaves Llc Photomodulation methods and devices for regulating cell proliferation and gene expression
US20060069340A1 (en) * 2003-06-16 2006-03-30 Solx, Inc. Shunt for the treatment of glaucoma
EP1638508B1 (en) 2003-06-16 2014-08-13 Solx, Inc. Shunt for the treatment of glaucoma
JP2007531544A (en) * 2003-07-11 2007-11-08 リライアント・テクノロジーズ・インコーポレイテッドReliant Technologies, Inc. Method and apparatus for fractionation phototherapy of skin
ES2572976T3 (en) 2003-07-31 2016-06-03 Gentlewaves Llc System and method for photodynamic treatment of skin
US20050065577A1 (en) * 2003-09-23 2005-03-24 Mcarthur Frank G. Low level laser tissue treatment
US7282060B2 (en) * 2003-12-23 2007-10-16 Reliant Technologies, Inc. Method and apparatus for monitoring and controlling laser-induced tissue treatment
US7309335B2 (en) * 2003-12-31 2007-12-18 Palomar Medical Technologies, Inc. Dermatological treatment with visualization
CA2457214A1 (en) * 2004-02-06 2005-08-06 Morgan Chun Lam Photodynamic therapy for the treatment of acne
ES2400566T3 (en) * 2004-06-09 2013-04-10 Qlt, Inc. Photodynamic therapy for the treatment of overactive sebaceous glands disorders using verteporfin and / or topically applied lemuteporfin
ES2611284T3 (en) 2004-04-01 2017-05-08 The General Hospital Corporation Apparatus for skin treatment and tissue remodeling
US20060020309A1 (en) * 2004-04-09 2006-01-26 Palomar Medical Technologies, Inc. Methods and products for producing lattices of EMR-treated islets in tissues, and uses therefor
US8235909B2 (en) 2004-05-12 2012-08-07 Guided Therapy Systems, L.L.C. Method and system for controlled scanning, imaging and/or therapy
US7413572B2 (en) * 2004-06-14 2008-08-19 Reliant Technologies, Inc. Adaptive control of optical pulses for laser medicine
US20080015554A1 (en) 2004-07-16 2008-01-17 Cole Curtis A Treatment of skin with light and a benefit agent to mitigate acne
US9011336B2 (en) 2004-09-16 2015-04-21 Guided Therapy Systems, Llc Method and system for combined energy therapy profile
US7393325B2 (en) 2004-09-16 2008-07-01 Guided Therapy Systems, L.L.C. Method and system for ultrasound treatment with a multi-directional transducer
US7824348B2 (en) 2004-09-16 2010-11-02 Guided Therapy Systems, L.L.C. System and method for variable depth ultrasound treatment
US7530958B2 (en) * 2004-09-24 2009-05-12 Guided Therapy Systems, Inc. Method and system for combined ultrasound treatment
US8535228B2 (en) 2004-10-06 2013-09-17 Guided Therapy Systems, Llc Method and system for noninvasive face lifts and deep tissue tightening
US8133180B2 (en) 2004-10-06 2012-03-13 Guided Therapy Systems, L.L.C. Method and system for treating cellulite
US8444562B2 (en) 2004-10-06 2013-05-21 Guided Therapy Systems, Llc System and method for treating muscle, tendon, ligament and cartilage tissue
US8690778B2 (en) 2004-10-06 2014-04-08 Guided Therapy Systems, Llc Energy-based tissue tightening
US7758524B2 (en) 2004-10-06 2010-07-20 Guided Therapy Systems, L.L.C. Method and system for ultra-high frequency ultrasound treatment
DK1855759T3 (en) * 2004-10-06 2017-06-06 Guided Therapy Systems Llc A system for ultrasonic treatment of tissue
CA2583600A1 (en) 2004-10-06 2006-04-20 Guided Therapy Systems, L.L.C. Method and system for noninvasive cosmetic enhancement
US9694212B2 (en) 2004-10-06 2017-07-04 Guided Therapy Systems, Llc Method and system for ultrasound treatment of skin
US9827449B2 (en) 2004-10-06 2017-11-28 Guided Therapy Systems, L.L.C. Systems for treating skin laxity
US7530356B2 (en) * 2004-10-06 2009-05-12 Guided Therapy Systems, Inc. Method and system for noninvasive mastopexy
US20060111744A1 (en) 2004-10-13 2006-05-25 Guided Therapy Systems, L.L.C. Method and system for treatment of sweat glands
GB0424833D0 (en) * 2004-11-10 2004-12-15 Photocure Asa Method
US8277495B2 (en) * 2005-01-13 2012-10-02 Candela Corporation Method and apparatus for treating a diseased nail
US20060253176A1 (en) * 2005-02-18 2006-11-09 Palomar Medical Technologies, Inc. Dermatological treatment device with deflector optic
BRPI0607903A2 (en) * 2005-02-18 2009-10-20 Palomar Medical Tech Inc dermatological treatment device
US7892269B2 (en) * 2005-04-18 2011-02-22 Zoll Circulation, Inc. External heat exchange pad for patient
JP4695188B2 (en) 2005-04-25 2011-06-08 アーデント サウンド, インコーポレイテッド Method and apparatus for improving the safety of the computer peripherals
US20070176262A1 (en) * 2005-08-11 2007-08-02 Ernest Sirkin Series connection of a diode laser bar
US20080058782A1 (en) * 2006-08-29 2008-03-06 Reliant Technologies, Inc. Method and apparatus for monitoring and controlling density of fractional tissue treatments
JP2009506835A (en) * 2005-08-29 2009-02-19 リライアント・テクノロジーズ・インコーポレイテッドReliant Technologies, Inc. Method and apparatus for monitoring and controlling the thermally-induced tissue treatment
US20070173799A1 (en) * 2005-09-01 2007-07-26 Hsia James C Treatment of fatty tissue adjacent an eye
AU2006292526A1 (en) 2005-09-15 2007-03-29 Palomar Medical Technologies, Inc. Skin optical characterization device
WO2007038567A1 (en) * 2005-09-28 2007-04-05 Candela Corporation Treating cellulite
US20070083190A1 (en) * 2005-10-11 2007-04-12 Yacov Domankevitz Compression device for a laser handpiece
US20070100401A1 (en) * 2005-11-01 2007-05-03 Lin J T Compact laser device and method for hair removal
US20070135876A1 (en) * 2005-12-08 2007-06-14 Weber Paul J Acne and skin defect treatment via non-radiofrequency electrical current controlled power delivery device and methods
US7891362B2 (en) * 2005-12-23 2011-02-22 Candela Corporation Methods for treating pigmentary and vascular abnormalities in a dermal region
US8033284B2 (en) 2006-01-11 2011-10-11 Curaelase, Inc. Therapeutic laser treatment
US20070194717A1 (en) * 2006-02-17 2007-08-23 Palomar Medical Technologies, Inc. Lamp for use in a tissue treatment device
US20070239142A1 (en) * 2006-03-10 2007-10-11 Palomar Medical Technologies, Inc. Photocosmetic device
US20070219604A1 (en) * 2006-03-20 2007-09-20 Palomar Medical Technologies, Inc. Treatment of tissue with radiant energy
US20070255355A1 (en) * 2006-04-06 2007-11-01 Palomar Medical Technologies, Inc. Apparatus and method for skin treatment with compression and decompression
US20070264626A1 (en) * 2006-05-11 2007-11-15 Reliant Technologies, Inc. Apparatus and Method for a Combination of Ablative and Nonablative Dermatological Treatment
US20070264625A1 (en) * 2006-05-11 2007-11-15 Reliant Technologies, Inc. Apparatus and Method for Ablation-Related Dermatological Treatment of Selected Targets
US8246611B2 (en) 2006-06-14 2012-08-21 Candela Corporation Treatment of skin by spatial modulation of thermal heating
US7586957B2 (en) 2006-08-02 2009-09-08 Cynosure, Inc Picosecond laser apparatus and methods for its operation and use
US20080161745A1 (en) * 2006-09-08 2008-07-03 Oliver Stumpp Bleaching of contrast enhancing agent applied to skin for use with a dermatological treatment system
US9566454B2 (en) 2006-09-18 2017-02-14 Guided Therapy Systems, Llc Method and sysem for non-ablative acne treatment and prevention
US20080161782A1 (en) * 2006-10-26 2008-07-03 Reliant Technologies, Inc. Micropore delivery of active substances
US20080186591A1 (en) * 2007-02-01 2008-08-07 Palomar Medical Technologies, Inc. Dermatological device having a zoom lens system
US20080208295A1 (en) * 2007-02-28 2008-08-28 Cumbie William E Phototherapy Treatment and Device to Improve the Appearance of Nails and skin
US20080221649A1 (en) * 2007-03-09 2008-09-11 Agustina Echague Method of sequentially treating tissue
US20100114086A1 (en) * 2007-04-19 2010-05-06 Deem Mark E Methods, devices, and systems for non-invasive delivery of microwave therapy
EP2837351B1 (en) 2007-04-19 2018-05-30 Miramar Labs, Inc. Systems for creating an effect using microwave energy to specified tissue
ES2471971T3 (en) 2007-12-12 2014-06-27 Miramar Labs, Inc. System and apparatus for non-invasive treatment of tissue using microwave energy
US8688228B2 (en) * 2007-04-19 2014-04-01 Miramar Labs, Inc. Systems, apparatus, methods and procedures for the noninvasive treatment of tissue using microwave energy
EP2142129A4 (en) * 2007-04-19 2011-04-20 Miramar Labs Inc Methods and apparatus for reducing sweat production
EP2271276A4 (en) * 2008-04-17 2013-01-23 Miramar Labs Inc Systems, apparatus, methods and procedures for the noninvasive treatment of tissue using microwave energy
TWI526233B (en) 2007-05-07 2016-03-21 Guided Therapy Systems Llc Methods and systems for modulating medicants using acoustic energy
EP2152167B1 (en) 2007-05-07 2018-09-05 Guided Therapy Systems, L.L.C. Methods and systems for coupling and focusing acoustic energy using a coupler member
US20080287931A1 (en) * 2007-05-18 2008-11-20 Jones Dennis R Use of iontophoresis and ultrasound to deliver melanin or other chromophores for laser hair removal
US20090192438A1 (en) * 2008-01-25 2009-07-30 Jones Dennis R Use of Iontophoresis or Electrotherapy and Ultrasound to Deliver Melanin for Skin Rejuvenation
US20090246270A1 (en) * 2008-01-31 2009-10-01 Jones Dennis R Use of Iontophoresis or Electrotherapy and Ultrasound to Deliver Agents for Skin Rejuvenation.
AU2009256007B2 (en) * 2008-06-06 2014-04-03 Ulthera, Inc. A system and method for cosmetic treatment and imaging
WO2010017556A1 (en) * 2008-08-08 2010-02-11 Palomar Medical Technologies, Inc Method and apparatus for fractional deformation and treatment of cutaneous and subcutaneous tissue
US20100100083A1 (en) * 2008-10-22 2010-04-22 Scott Lundahl Method of treatment for dermatologic disorders
EP2365829B1 (en) 2008-11-07 2017-05-24 KLOX Technologies, Inc. Combination of an oxidant and a photoactivator for the healing of wounds
JP2012513837A (en) 2008-12-24 2012-06-21 ガイデッド セラピー システムズ, エルエルシー Method and system for fat loss and / or cellulite treatment
EP2451796B1 (en) 2009-07-08 2013-04-17 Dermira (Canada), Inc. Tofa analogs useful in treating dermatological disorders or conditions
SG10201700310PA (en) 2009-07-17 2017-03-30 Klox Technologies Inc Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease
US9919168B2 (en) 2009-07-23 2018-03-20 Palomar Medical Technologies, Inc. Method for improvement of cellulite appearance
US8715186B2 (en) 2009-11-24 2014-05-06 Guided Therapy Systems, Llc Methods and systems for generating thermal bubbles for improved ultrasound imaging and therapy
US20110190745A1 (en) * 2009-12-04 2011-08-04 Uebelhoer Nathan S Treatment of sweat glands
US20110172746A1 (en) * 2010-01-12 2011-07-14 Roger Porter High Level Laser Therapy Apparatus and Methods
US9504446B2 (en) 2010-08-02 2016-11-29 Guided Therapy Systems, Llc Systems and methods for coupling an ultrasound source to tissue
KR20140047709A (en) 2011-07-11 2014-04-22 가이디드 테라피 시스템스, 엘.엘.씨. Systems and methods for coupling an ultrasound source to tissue
WO2012018391A2 (en) 2010-08-02 2012-02-09 Guided Therapy Systems, Llc Methods and systems for treating plantar fascia
US8857438B2 (en) 2010-11-08 2014-10-14 Ulthera, Inc. Devices and methods for acoustic shielding
FR2968569B1 (en) 2010-12-13 2013-01-04 Oreal Process for treatment of non-acne oily skin.
US8858471B2 (en) 2011-07-10 2014-10-14 Guided Therapy Systems, Llc Methods and systems for ultrasound treatment
US9314301B2 (en) 2011-08-01 2016-04-19 Miramar Labs, Inc. Applicator and tissue interface module for dermatological device
US9510802B2 (en) 2012-09-21 2016-12-06 Guided Therapy Systems, Llc Reflective ultrasound technology for dermatological treatments
US9263663B2 (en) 2012-04-13 2016-02-16 Ardent Sound, Inc. Method of making thick film transducer arrays
EP2839552A4 (en) 2012-04-18 2015-12-30 Cynosure Inc Picosecond laser apparatus and methods for treating target tissues with same
US20130281913A1 (en) 2012-04-20 2013-10-24 Klox Technologies Inc. Biophotonic compositions and methods for providing biophotonic treatment
FR2991870B1 (en) 2012-06-13 2015-08-21 Oreal Process for the treatment of oily skin
US20140276354A1 (en) * 2013-03-14 2014-09-18 Klox Technologies Inc. Biophotonic materials and uses thereof
JP2017501857A (en) 2014-01-10 2017-01-19 セバシア,インコーポレイテッド Particles containers and delivery applicator
MX2016012933A (en) 2014-04-01 2016-12-07 Klox Tech Inc Tissue filler compositions and methods of use.
US9907975B1 (en) 2014-11-19 2018-03-06 Roger D. Porter Therapeutic laser treatment and transdermal stimulation of stem cell differentiation

Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287554A (en) * 1978-07-03 1981-09-01 Friedrich Wolff Radiation apparatus
US4651739A (en) * 1985-04-08 1987-03-24 The General Hospital Corporation Light-induced killing of carcinoma cells
US4803069A (en) * 1985-06-18 1989-02-07 Biogal Gyogyszergyar Composition for the treatment of acne
US4930504A (en) * 1987-11-13 1990-06-05 Diamantopoulos Costas A Device for biostimulation of tissue and method for treatment of tissue
US4945908A (en) * 1985-11-07 1990-08-07 Karl Schneider Balneo-phototherapeutical treatment process and bath
US5019034A (en) * 1988-01-21 1991-05-28 Massachusetts Institute Of Technology Control of transport of molecules across tissue using electroporation
US5131403A (en) * 1991-06-05 1992-07-21 Becton Dickinson And Company Method for obtaining blood using iontophoresis
US5226907A (en) * 1991-10-29 1993-07-13 Tankovich Nikolai I Hair removal device and method
US5234940A (en) * 1989-07-28 1993-08-10 Queen's University Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof
US5304170A (en) * 1993-03-12 1994-04-19 Green Howard A Method of laser-induced tissue necrosis in carotenoid-containing skin structures
US5422093A (en) * 1989-07-28 1995-06-06 Queen's University Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof
US5423803A (en) * 1991-10-29 1995-06-13 Thermotrex Corporation Skin surface peeling process using laser
US5425728A (en) * 1991-10-29 1995-06-20 Tankovich; Nicolai I. Hair removal device and method
US5442611A (en) * 1992-05-07 1995-08-15 Olympus Optical Co., Ltd. Method of recording information on record medium having data record region and file management information record region
US5464436A (en) * 1994-04-28 1995-11-07 Lasermedics, Inc. Method of performing laser therapy
US5520905A (en) * 1993-06-24 1996-05-28 Beiersdorf Aktiengesellschaft Cosmetic or dermatological preparation comprising delta-aminolevulinic acid content as an active ingredient
US5633275A (en) * 1995-09-06 1997-05-27 Meiji Seika Kaisha, Ltd. Photochemotherapeutical obstruction of newly-formed blood vessels
US5647866A (en) * 1993-11-09 1997-07-15 Zaias; Nardo Method of hair depilation
US5713845A (en) * 1991-10-29 1998-02-03 Thermolase Corporation Laser assisted drug delivery
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5735844A (en) * 1995-02-01 1998-04-07 The General Hospital Corporation Hair removal using optical pulses
US5752949A (en) * 1991-10-29 1998-05-19 Thermolase Corporation Hair removal method
US5752948A (en) * 1991-10-29 1998-05-19 Thermolase Corporation Hair removal method
US5817089A (en) * 1991-10-29 1998-10-06 Thermolase Corporation Skin treatment process using laser
US5856566A (en) * 1997-09-02 1999-01-05 Dusa Pharmaceuticals, Inc. Sterilized 5-aminolevulinic acid
US5925034A (en) * 1994-08-23 1999-07-20 Sisters Of Providence In Oregon Method and apparatus for determination of psoralen concentrations in biological tissues
US5955490A (en) * 1989-07-28 1999-09-21 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US6063108A (en) * 1997-01-06 2000-05-16 Salansky; Norman Method and apparatus for localized low energy photon therapy (LEPT)
US6165170A (en) * 1998-01-29 2000-12-26 International Business Machines Corporation Laser dermablator and dermablation
US6168590B1 (en) * 1997-08-12 2001-01-02 Y-Beam Technologies, Inc. Method for permanent hair removal
US6183773B1 (en) * 1999-01-04 2001-02-06 The General Hospital Corporation Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
US6306130B1 (en) * 1998-04-07 2001-10-23 The General Hospital Corporation Apparatus and methods for removing blood vessels
US6358272B1 (en) * 1995-05-16 2002-03-19 Lutz Wilden Therapy apparatus with laser irradiation device
US6408212B1 (en) * 1999-04-13 2002-06-18 Joseph Neev Method for treating acne
US20020087205A1 (en) * 1999-01-15 2002-07-04 Light Sciences Corporation Transcutaneous photodynamic treatment of targeted cells
US6663658B1 (en) * 1999-04-27 2003-12-16 The General Hospital Corporation Phototherapy method for treatment of acne
US20080051773A1 (en) * 1997-10-08 2008-02-28 Sergei Ivanov Automated Treatment of Psoriasis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0831909B1 (en) 1995-06-05 2005-01-26 Queen's University at Kingston Use of a protoporphyrin ix precursor in the treatment of dermatophytoses and malaria after photoactivation of said protoporphyrin
WO1994006424A1 (en) 1992-09-21 1994-03-31 Quadra Logic Technologies, Inc. Transcutaneous in vivo activation of photosensitive agents in blood
GB9318841D0 (en) 1993-09-10 1993-10-27 Res Foundation Of The Norwegia Composition
US5445611A (en) * 1993-12-08 1995-08-29 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal delivery with ultrasound and chemical enhancers
US5669916A (en) * 1994-09-28 1997-09-23 The General Hospital Corporation Method of hair removal
DE4440112A1 (en) 1994-11-11 1996-05-15 Jan H Dr Wilkens Appts. for treating skin disorder esp. psoriasis with radiation
US5643334A (en) 1995-02-07 1997-07-01 Esc Medical Systems Ltd. Method and apparatus for the diagnostic and composite pulsed heating and photodynamic therapy treatment
US6056738A (en) 1997-01-31 2000-05-02 Transmedica International, Inc. Interstitial fluid monitoring
IL120891D0 (en) 1997-05-22 1997-09-30 Technion Res & Dev Foundation Photodynamic and sonodynamic therapy and agents for use therefor
IL120943A (en) * 1997-05-29 2004-03-28 Univ Ben Gurion Transdermal delivery system
US6283956B1 (en) * 1998-11-30 2001-09-04 David H. McDaniels Reduction, elimination, or stimulation of hair growth

Patent Citations (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287554A (en) * 1978-07-03 1981-09-01 Friedrich Wolff Radiation apparatus
US4651739A (en) * 1985-04-08 1987-03-24 The General Hospital Corporation Light-induced killing of carcinoma cells
US4803069A (en) * 1985-06-18 1989-02-07 Biogal Gyogyszergyar Composition for the treatment of acne
US4945908A (en) * 1985-11-07 1990-08-07 Karl Schneider Balneo-phototherapeutical treatment process and bath
US4930504A (en) * 1987-11-13 1990-06-05 Diamantopoulos Costas A Device for biostimulation of tissue and method for treatment of tissue
US5019034A (en) * 1988-01-21 1991-05-28 Massachusetts Institute Of Technology Control of transport of molecules across tissue using electroporation
US5019034B1 (en) * 1988-01-21 1995-08-15 Massachusetts Inst Technology Control of transport of molecules across tissue using electroporation
US5955490A (en) * 1989-07-28 1999-09-21 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US5234940A (en) * 1989-07-28 1993-08-10 Queen's University Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof
US5422093A (en) * 1989-07-28 1995-06-06 Queen's University Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5131403A (en) * 1991-06-05 1992-07-21 Becton Dickinson And Company Method for obtaining blood using iontophoresis
US5817089A (en) * 1991-10-29 1998-10-06 Thermolase Corporation Skin treatment process using laser
US6036684A (en) * 1991-10-29 2000-03-14 Thermolase Corporation Skin treatment process using laser
US5423803A (en) * 1991-10-29 1995-06-13 Thermotrex Corporation Skin surface peeling process using laser
US5752949A (en) * 1991-10-29 1998-05-19 Thermolase Corporation Hair removal method
US5226907A (en) * 1991-10-29 1993-07-13 Tankovich Nikolai I Hair removal device and method
US5425728A (en) * 1991-10-29 1995-06-20 Tankovich; Nicolai I. Hair removal device and method
US5713845A (en) * 1991-10-29 1998-02-03 Thermolase Corporation Laser assisted drug delivery
US5752948A (en) * 1991-10-29 1998-05-19 Thermolase Corporation Hair removal method
US5442611A (en) * 1992-05-07 1995-08-15 Olympus Optical Co., Ltd. Method of recording information on record medium having data record region and file management information record region
US5304170A (en) * 1993-03-12 1994-04-19 Green Howard A Method of laser-induced tissue necrosis in carotenoid-containing skin structures
US5520905A (en) * 1993-06-24 1996-05-28 Beiersdorf Aktiengesellschaft Cosmetic or dermatological preparation comprising delta-aminolevulinic acid content as an active ingredient
US5647866A (en) * 1993-11-09 1997-07-15 Zaias; Nardo Method of hair depilation
US5464436A (en) * 1994-04-28 1995-11-07 Lasermedics, Inc. Method of performing laser therapy
US5925034A (en) * 1994-08-23 1999-07-20 Sisters Of Providence In Oregon Method and apparatus for determination of psoralen concentrations in biological tissues
US5735844A (en) * 1995-02-01 1998-04-07 The General Hospital Corporation Hair removal using optical pulses
US6358272B1 (en) * 1995-05-16 2002-03-19 Lutz Wilden Therapy apparatus with laser irradiation device
US5633275A (en) * 1995-09-06 1997-05-27 Meiji Seika Kaisha, Ltd. Photochemotherapeutical obstruction of newly-formed blood vessels
US6063108A (en) * 1997-01-06 2000-05-16 Salansky; Norman Method and apparatus for localized low energy photon therapy (LEPT)
US6168590B1 (en) * 1997-08-12 2001-01-02 Y-Beam Technologies, Inc. Method for permanent hair removal
US5856566A (en) * 1997-09-02 1999-01-05 Dusa Pharmaceuticals, Inc. Sterilized 5-aminolevulinic acid
US20080051773A1 (en) * 1997-10-08 2008-02-28 Sergei Ivanov Automated Treatment of Psoriasis
US6165170A (en) * 1998-01-29 2000-12-26 International Business Machines Corporation Laser dermablator and dermablation
US6306130B1 (en) * 1998-04-07 2001-10-23 The General Hospital Corporation Apparatus and methods for removing blood vessels
US6600951B1 (en) * 1999-01-04 2003-07-29 The General Hospital Corporation Targeting of sebaceous follicles as a Treatment of sebaceous gland disorders
US6183773B1 (en) * 1999-01-04 2001-02-06 The General Hospital Corporation Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
US20020087205A1 (en) * 1999-01-15 2002-07-04 Light Sciences Corporation Transcutaneous photodynamic treatment of targeted cells
US6408212B1 (en) * 1999-04-13 2002-06-18 Joseph Neev Method for treating acne
US7020528B2 (en) * 1999-04-13 2006-03-28 Joseph Neev Method for treating acne
US6663658B1 (en) * 1999-04-27 2003-12-16 The General Hospital Corporation Phototherapy method for treatment of acne

Cited By (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981111B2 (en) 2003-02-25 2011-07-19 Tria Beauty, Inc. Method and apparatus for the treatment of benign pigmented lesions
US20040167502A1 (en) * 2003-02-25 2004-08-26 Weckwerth Mark V. Optical sensor and method for identifying the presence of skin
US20040167500A1 (en) * 2003-02-25 2004-08-26 Weckwerth Mark V. Self-contained, diode-laser-based dermatologic treatment apparatus and method
US20040176823A1 (en) * 2003-02-25 2004-09-09 Island Tobin C. Acne treatment device and method
US20040167499A1 (en) * 2003-02-25 2004-08-26 Grove Robert E. Eye-safe dermatologic treatment apparatus and method
US8551104B2 (en) 2003-02-25 2013-10-08 Tria Beauty, Inc. Self-contained, diode-laser-based dermatologic treatment apparatus
US20080027518A1 (en) * 2003-02-25 2008-01-31 Spectragenics, Inc. Self-contained, eye-safe hair-regrowth-inhibition apparatus and method
US20070032847A1 (en) * 2003-02-25 2007-02-08 Spectragenics, Inc. Self-contained, diode-laser-based dermatologic treatment apparatus
US20090043294A1 (en) * 2003-02-25 2009-02-12 Spectragenics, Inc. Capacitive Sensing Method and Device for Detecting Skin
US20090204109A1 (en) * 2003-02-25 2009-08-13 Tria Beauty, Inc. Eye-Safe Dermatologic Treatment Apparatus and Method
US8709003B2 (en) 2003-02-25 2014-04-29 Tria Beauty, Inc. Capacitive sensing method and device for detecting skin
US20040176754A1 (en) * 2003-03-06 2004-09-09 Island Tobin C. Method and device for sensing skin contact
US20050038473A1 (en) * 2003-07-14 2005-02-17 Dov Tamarkin Device and method for the treatment of pilosebaceous disorders
WO2005004984A1 (en) * 2003-07-14 2005-01-20 Power Paper Ltd. Device and method for the treatment of pilosebaceous disorders
US8777935B2 (en) 2004-02-25 2014-07-15 Tria Beauty, Inc. Optical sensor and method for identifying the presence of skin
US8337539B2 (en) 2006-02-22 2012-12-25 Zeltiq Aesthetics, Inc. Cooling device for removing heat from subcutaneous lipid-rich cells
US20070198071A1 (en) * 2006-02-22 2007-08-23 Juniper Medical Systems Cooling device for removing heat from subcutaneous lipid-rich cells
US7854754B2 (en) 2006-02-22 2010-12-21 Zeltiq Aesthetics, Inc. Cooling device for removing heat from subcutaneous lipid-rich cells
US20070255362A1 (en) * 2006-04-28 2007-11-01 Juniper Medical, Inc. Cryoprotectant for use with a cooling device for improved cooling of subcutaneous lipid-rich cells
US9375345B2 (en) 2006-09-26 2016-06-28 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US9132031B2 (en) 2006-09-26 2015-09-15 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US8192474B2 (en) 2006-09-26 2012-06-05 Zeltiq Aesthetics, Inc. Tissue treatment methods
US20080077211A1 (en) * 2006-09-26 2008-03-27 Juniper Medical, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US20080077202A1 (en) * 2006-09-26 2008-03-27 Juniper Medical, Inc. Tissue Treatment Methods
US20080077201A1 (en) * 2006-09-26 2008-03-27 Juniper Medical, Inc. Cooling devices with flexible sensors
US20080208179A1 (en) * 2006-10-26 2008-08-28 Reliant Technologies, Inc. Methods of increasing skin permeability by treatment with electromagnetic radiation
WO2008052198A3 (en) * 2006-10-26 2008-06-26 Vikramaditya P Bedi Methods of increasing skin permeability by treatment with electromagnetic radiation
WO2008052198A2 (en) * 2006-10-26 2008-05-02 Reliant Technologies, Inc. Methods of increasing skin permeability by treatment with electromagnetic radiation
US20080287839A1 (en) * 2007-05-18 2008-11-20 Juniper Medical, Inc. Method of enhanced removal of heat from subcutaneous lipid-rich cells and treatment apparatus having an actuator
US9108045B2 (en) 2007-06-27 2015-08-18 The General Hospital Corporation Method and apparatus for optical inhibition of photodynamic therapy
US8523927B2 (en) 2007-07-13 2013-09-03 Zeltiq Aesthetics, Inc. System for treating lipid-rich regions
US20090018623A1 (en) * 2007-07-13 2009-01-15 Juniper Medical, Inc. System for treating lipid-rich regions
US20090018626A1 (en) * 2007-07-13 2009-01-15 Juniper Medical, Inc. User interfaces for a system that removes heat from lipid-rich regions
US9655770B2 (en) 2007-07-13 2017-05-23 Zeltiq Aesthetics, Inc. System for treating lipid-rich regions
US20090018625A1 (en) * 2007-07-13 2009-01-15 Juniper Medical, Inc. Managing system temperature to remove heat from lipid-rich regions
US20090018624A1 (en) * 2007-07-13 2009-01-15 Juniper Medical, Inc. Limiting use of disposable system patient protection devices
US9408745B2 (en) 2007-08-21 2016-08-09 Zeltiq Aesthetics, Inc. Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
US8285390B2 (en) 2007-08-21 2012-10-09 Zeltiq Aesthetics, Inc. Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
US20110066127A1 (en) * 2008-03-31 2011-03-17 Seiichi Kuwano Disposable absorbent wearing article
US9687671B2 (en) 2008-04-25 2017-06-27 Channel Investments, Llc Optical sensor and method for identifying the presence of skin and the pigmentation of skin
US20090270848A1 (en) * 2008-04-25 2009-10-29 Tria Beauty, Inc. Optical Sensor and Method for Identifying the Presence of Skin and the Pigmentation of Skin
US8275442B2 (en) 2008-09-25 2012-09-25 Zeltiq Aesthetics, Inc. Treatment planning systems and methods for body contouring applications
US20100081971A1 (en) * 2008-09-25 2010-04-01 Allison John W Treatment planning systems and methods for body contouring applications
US8603073B2 (en) 2008-12-17 2013-12-10 Zeltiq Aesthetics, Inc. Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells
US20100152824A1 (en) * 2008-12-17 2010-06-17 Allison John W Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells
US9737434B2 (en) 2008-12-17 2017-08-22 Zeltiq Aestehtics, Inc. Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells
US8702774B2 (en) 2009-04-30 2014-04-22 Zeltiq Aesthetics, Inc. Device, system and method of removing heat from subcutaneous lipid-rich cells
US9861520B2 (en) 2009-04-30 2018-01-09 Zeltiq Aesthetics, Inc. Device, system and method of removing heat from subcutaneous lipid-rich cells
US20100280582A1 (en) * 2009-04-30 2010-11-04 Zeltiq Aesthetics, Inc. Device, system and method of removing heat from subcutaneous lipid-rich cells
US9687508B2 (en) 2009-05-26 2017-06-27 The General Hospital Corporation Methods for alleviating acne and methods for treating a sebaceous gland
US20110034855A1 (en) * 2009-06-23 2011-02-10 Board Of Regents, The University Of Texas System Noninvasive therapies in the absence or presence of exogenous particulate agents
US9931516B2 (en) 2009-06-23 2018-04-03 Board Of Regents, The University Of Texas System Noninvasive therapies in the presence of exogenous particulate agents
US9504824B2 (en) * 2009-06-23 2016-11-29 Board Of Regents, The University Of Texas System Noninvasive therapies in the absence or presence of exogenous particulate agents
US9844461B2 (en) 2010-01-25 2017-12-19 Zeltiq Aesthetics, Inc. Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants
US20110238050A1 (en) * 2010-01-25 2011-09-29 Zeltiq Aesthetics, Inc. Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants, and associates devices, systems and methods
US9314368B2 (en) 2010-01-25 2016-04-19 Zeltiq Aesthetics, Inc. Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants, and associates devices, systems and methods
US8676338B2 (en) 2010-07-20 2014-03-18 Zeltiq Aesthetics, Inc. Combined modality treatment systems, methods and apparatus for body contouring applications
US10092346B2 (en) 2010-07-20 2018-10-09 Zeltiq Aesthetics, Inc. Combined modality treatment systems, methods and apparatus for body contouring applications
US20140371655A1 (en) * 2010-08-27 2014-12-18 Sienna Labs, Inc. Thermal treatment of acne with coated metal nanoparticles
US20140371659A1 (en) * 2010-08-27 2014-12-18 Sienna Labs, Inc. Hair removal with metal nanoparticles in surfactant containing solutions
US20150005691A1 (en) * 2010-08-27 2015-01-01 Sienna Labs, Inc. Thermal treatment of a pilosebaceous unit with metal nanoparticles in surfactant containing solutions
US9061056B2 (en) 2010-08-27 2015-06-23 Sienna Labs, Inc. Compositions and methods for targeted thermomodulation
US8906418B1 (en) 2010-08-27 2014-12-09 Sienna Labs, Inc. Thermal treatment of a pilosebaceous unit with nanoparticles with coatings that facilitate selective removal from the skin surface
US20140371654A1 (en) * 2010-08-27 2014-12-18 Sienna Labs, Inc. Hair removal with nanoparticles with coatings that facilitate selective removal from the skin surface
US20140371661A1 (en) * 2010-08-27 2014-12-18 Sienna Labs, Inc. Thermal treatment of the skin surface with coated metal nanoparticles
US20140371658A1 (en) * 2010-08-27 2014-12-18 Sienna Labs, Inc. Thermal treatment of acne with metal nanoparticles in surfactant containing solutions
US20140371663A1 (en) * 2010-08-27 2014-12-18 Sienna Labs, Inc. Thermal treatment of acne with nanoparticles with coatings that facilitate selective removal from the skin surface
US20140371656A1 (en) * 2010-08-27 2014-12-18 Sienna Labs, Inc. Hair removal with coated metal nanoparticles
US20140371662A1 (en) * 2010-08-27 2014-12-18 Sienna Labs, Inc. Thermal treatment of the skin surface with metal nanoparticles in surfactant containing solutions
US20140371664A1 (en) * 2010-08-27 2014-12-18 Sienna Labs, Inc. Thermal treatment of the skin surface with nanoparticles with coatings that facilitate selective removal from the skin surface
US8895071B1 (en) 2010-08-27 2014-11-25 Sienna Labs, Inc. Thermal treatment of a pilosebaceous unit with coated metal nanoparticles
US9421259B2 (en) * 2010-08-27 2016-08-23 Sienna Biopharmaceuticals, Inc. Hair removal with coated metal nanoparticles
US9421261B2 (en) * 2010-08-27 2016-08-23 Sienna Biopharmaceuticals, Inc. Thermal treatment of the skin surface with nanoparticles with coatings that facilitate selective removal from the skin surface
US8834933B2 (en) * 2010-08-27 2014-09-16 Sienna Labs, Inc. Thermal treatment of acne with nanoparticles
US9427467B2 (en) * 2010-08-27 2016-08-30 Sienna Biopharmaceuticals, Inc. Hair removal with metal nanoparticles in surfactant containing solutions
US9433678B2 (en) * 2010-08-27 2016-09-06 Sienna Biopharmaceuticals, Inc. Thermal treatment of acne with metal nanoparticles in surfactant containing solutions
US9433676B2 (en) * 2010-08-27 2016-09-06 Sienna Biopharmaceuticals, Inc. Hair removal with nanoparticles with coatings that facilitate selective removal from the skin surface
US9433677B2 (en) * 2010-08-27 2016-09-06 Sienna Biopharmaceuticals, Inc. Thermal treatment of a pilosebaceous unit with metal nanoparticles in surfactant containing solutions
US8821940B2 (en) * 2010-08-27 2014-09-02 Sienna Labs, Inc. Thermal treatment of the skin surface with nanoparticles
US9439964B2 (en) * 2010-08-27 2016-09-13 Sienna Biopharmaceuticals, Inc. Thermal treatment of the skin surface with coated metal nanoparticles
US9446126B2 (en) * 2010-08-27 2016-09-20 Sienna Biopharmaceuticals, Inc. Thermal treatment of acne with coated metal nanoparticles
US8821941B2 (en) * 2010-08-27 2014-09-02 Sienna Labs, Inc. Hair removal with nanoparticles
US8802154B2 (en) * 2010-08-27 2014-08-12 Sienna Labs, Inc. Thermal treatment of a pilosebaceous unit with nanoparticles
US9572880B2 (en) 2010-08-27 2017-02-21 Sienna Biopharmaceuticals, Inc. Ultrasound delivery of nanoparticles
US20140012163A1 (en) * 2010-08-27 2014-01-09 Sienna Labs, Inc. Thermal Treatment of Acne with Nanoparticles
US9439965B2 (en) * 2010-08-27 2016-09-13 Sienna Biopharmaceuticals, Inc. Thermal treatment of the skin surface with metal nanoparticles in surfactant containing solutions
US9421260B2 (en) * 2010-08-27 2016-08-23 Sienna Biopharmaceuticals, Inc. Thermal treatment of acne with nanoparticles with coatings that facilitate selective removal from the skin surface
AU2016200848B2 (en) * 2010-08-27 2017-04-20 Sienna Biopharmaceuticals, Inc. Compositions and methods for targeted thermomodulation
US9333259B2 (en) 2012-05-08 2016-05-10 The Regents Of The University Of California Selective fat removal using NIR light and nanoparticles
US10188461B2 (en) 2012-05-08 2019-01-29 The Regents Of The University Of California Selective fat removal using photothermal heating
US9522289B2 (en) 2012-05-08 2016-12-20 The Regents Of The University Of California Selective fat removal using photothermal heating
US9333258B2 (en) 2012-05-08 2016-05-10 The Regents Of The University Of California Fine spatiotemporal control of fat removal using NIR light
US9526745B2 (en) 2012-10-11 2016-12-27 Nanocomposix, Inc. Silver nanoplate compositions and methods
US9212294B2 (en) 2012-10-11 2015-12-15 Nanocomposix, Inc. Silver nanoplate compositions and methods
US9249334B2 (en) 2012-10-11 2016-02-02 Nanocomposix, Inc. Silver nanoplate compositions and methods
US9545523B2 (en) 2013-03-14 2017-01-17 Zeltiq Aesthetics, Inc. Multi-modality treatment systems, methods and apparatus for altering subcutaneous lipid-rich tissue
US9844460B2 (en) 2013-03-14 2017-12-19 Zeltiq Aesthetics, Inc. Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same
US9861421B2 (en) 2014-01-31 2018-01-09 Zeltiq Aesthetics, Inc. Compositions, treatment systems and methods for improved cooling of lipid-rich tissue
US10201380B2 (en) 2014-01-31 2019-02-12 Zeltiq Aesthetics, Inc. Treatment systems, methods, and apparatuses for improving the appearance of skin and providing other treatments
USD777338S1 (en) 2014-03-20 2017-01-24 Zeltiq Aesthetics, Inc. Cryotherapy applicator for cooling tissue
WO2017176380A1 (en) * 2016-02-22 2017-10-12 The General Hospital Corporation Systems and methods for selective targeting of structural features in treating skin conditions

Also Published As

Publication number Publication date
US6600951B1 (en) 2003-07-29
ES2539794T3 (en) 2015-07-06
CA2360202A1 (en) 2000-07-13
US6183773B1 (en) 2001-02-06
DK1140180T3 (en) 2015-06-15
EP1140180B1 (en) 2015-04-01
WO2000040266A3 (en) 2001-01-18
WO2000040266A9 (en) 2000-11-23
WO2000040266A2 (en) 2000-07-13
EP1140180A2 (en) 2001-10-10
CA2360202C (en) 2013-02-19

Similar Documents

Publication Publication Date Title
Sadick Update on non‐ablative light therapy for rejuvenation: A review
Tanzi et al. Lasers in dermatology: four decades of progress
Nanni et al. Laser-assisted hair removal: side effects of Q-switched Nd: YAG, long-pulsed ruby, and alexandrite lasers
Wolf et al. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid: an alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas?
Lask et al. Laser‐assisted hair removal by selective photothermolysis preliminary results
US9579380B2 (en) Microporation of tissue for delivery of bioactive agents
JP4495894B2 (en) Apparatus for performing a medical treatment by using a long period of time of electromagnetic radiation
US7060061B2 (en) Method and apparatus for the selective targeting of lipid-rich tissues
DE69737836T2 (en) Microporation of tissue for delivery of bioactive substances
US6527716B1 (en) Microporation of tissue for delivery of bioactive agents
US8096982B2 (en) Method and apparatus to enhance optical transparency of biological tissues
US6629971B2 (en) Process for stimulating hair growth
Tuchin et al. A pilot study of ICG laser therapy of acne vulgaris: photodynamic and photothermolysis treatment
US5057104A (en) Method and apparatus for treating cutaneous vascular lesions
US6030374A (en) Ultrasound enhancement of percutaneous drug absorption
US6152917A (en) Hair removal device
KR101239925B1 (en) Method and apparatus for the stimulation of hair growth
US20080172047A1 (en) Methods And Devices For Fractional Ablation Of Tissue
US20080058783A1 (en) Handheld Photocosmetic Device
AU2011293132B2 (en) Compositions and methods for targeted thermomodulation
Raulin et al. Treatment of essential telangiectasias with an intense pulsed light source (PhotoDerm VL)
Marmur et al. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer
Weiss et al. Treatment of poikiloderma of Civatte with an intense pulsed light source
US20090069741A1 (en) Methods And Devices For Fractional Ablation Of Tissue For Substance Delivery
Lee et al. Laser-assisted topical drug delivery by using a low-fluence fractional laser: imiquimod and macromolecules